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Our first study identified the effects of maternal inflammation-induced
intrauterine growth restriction (MI-IUGR) on growth and muscle glucose metabolism in
offspring supplemented with curcumin. MI-IUGR lambs exhibited asymmetric growth
restriction at birth and 30d of age, but normal glucose-stimulated insulin secretion.
Hindlimb glucose oxidation was reduced by MI-IUGR and not improved by curcumin
supplementation. Ex vivo muscle glucose oxidation was reduced by MI-IUGR but
improved somewhat by curcumin. These finding indicate that fetal programming
responses to MI contribute to neonatal growth and metabolic deficits. Neonatal curcumin
supplementation had minimal effect on growth deficits but may improve glucose
metabolism.
Our second study identified programmed mechanistic changes that explain
intrinsic functional deficits in myoblasts from maternal hyperthermia-induced IUGR fetal
sheep. Myoblasts were incubated with TNF⍺, TNFα with IKK inhibitor (IKKi), or IL6.
Proliferation in IUGR myoblasts was less than controls in basal and IL6-spiked media.
IKKi decreased proliferation in all myoblasts, but more in IUGR myoblasts. IUGR
myoblasts differentiated less than controls, and TNF⍺ further reduced their

differentiation. TNFα increased TLR4 mRNA in all myoblasts, but more in IUGR
myoblasts. TNFR1 and ULK2 mRNA was greater in IUGR myoblasts. IL6 and TNFR1
mRNA and c-Fos protein were greater in IUGR semitendinosus muscle, but I𝜿B content
was reduced. These results demonstrate intrinsic enhancement of inflammatory signaling
and IKK pathways in IUGR myoblasts, which coincided with reduced functional
capacity.
A final study assessed stress-responsive mRNA biomarkers in blood. MI at midgestation altered blood mRNA expression in pregnant rats and fetuses. Blood TNFR1 was
increased in IUGR fetuses, but not when dams received meloxicam. Fetal IL6R and
maternal TNFR1 were reduced by IUGR with or without meloxicam. We also designed
ddPCR probes/primers to assess stress-responsive transcripts including
cytokines/receptors in blood from elephants, cheetahs, and giraffes. These studies
demonstrate stress-induced changes in blood transcriptomes of animals, which represent
novel stress biomarkers.
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Chapter 1: Literature Review

Introduction
Intrauterine growth restriction (IUGR) is a leading cause of perinatal morbidity
and mortality in both humans and animals (Alisi et al., 2011). Impaired growth and
development can result from a plethora of maternal stressors such as obesity,
inflammation, malnutrition, and environmental stress (Valsamakis et al., 2006). Previous
studies have linked IUGR to disproportionately reduced skeletal muscle growth during
prenatal development (Padoan et al., 2004; Yates et al., 2014). IUGR offspring present
with reduced muscle mass and increased risk of developing metabolic disorders at all
stages of life (Godfrey and Barker, 2000; Yates et al., 2018). These offspring continue to
demonstrate deficits in skeletal muscle growth throughout their lifespan (Greenwood et
al., 2000). Regardless of maternal insult, fetal growth restriction is usually caused by
reduced nutrient transfer to the fetus due to placental insufficiency leading to IUGR (PIIUGR) (Baschat, 2004; Cox and Marton, 2009). This leads to a poor in utero
environment during development and subjects the fetus to chronic hypoxemia,
hypoglycemia, hypertension, and hyperlactatemia (Thorn et al., 2011). In response,
adaptations occur in the fetal tissues to repartition nutrients to vital organs, leading to
impaired skeletal muscle growth and changes in leukocyte cell populations and
phenotypes (Godfrey and Barker, 2000; Martinez et al., 2014; Yates et al., 2018). These
adaptations, although beneficial in utero, lead to impaired metabolic function and
restricted skeletal muscle growth capacity throughout the lifespan. This “thrifty
phenotype” was first described by Hales and Barker (1992), who originally linked fetal

2
adaptations that lower birthweight to an increased risk of developing metabolic diseases
in adulthood. Epidemiological and seminal research studies describe the health outcomes
of these adaptations (Joyce et al., 2001; Sharma et al., 2016; Camacho et al., 2017b).
However, little is known about the underlying molecular mechanisms, particularly the
role that inflammation and other stress system signaling pathways play in the
development of these adaptions and the resulting IUGR phenotype.
Fetal Skeletal Muscle Growth and Development
Forty-percent of total body mass in the uncompromised term fetus is comprised of
skeletal muscle, which is found predominantly in the hindlimbs, neck and trunk areas
(Bentzinger et al., 2012; Felber et al., 2013; Brown, 2014). Muscle fibers are composed
from myoblasts that fuse during early prenatal development to form singular fibers with
multiple peripherally-located nuclei (Zammit et al., 2006; McCarthy et al., 2011). This
differentiates skeletal muscle from both cardiac and smooth muscle. Due to the presence
of actin and myosin filaments, which are responsible for the contraction and function,
skeletal muscle appears straited. This organ is highly metabolic, relying on both internal
and external stores of glucose and fatty acids for energy (Bentzinger et al., 2012; Felber
et al., 2013). Skeletal muscle is active throughout life and after birth continues to undergo
growth via hypertrophy, whereby existing fibers incorporate new myonuclei via
additional myoblast fusion (McCarthy et al., 2011). Hyperplasia, which is the formation
of new fibers from resident satellite stem cell populations is rare after birth in most
species, making the initial populations of fibers and myoblasts established in utero a
crucial point in development (Bentzinger et al., 2012).
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Myogenesis
Skeletal muscle plays a crucial role in glucose homeostasis and the metabolic
health of an individual, making its proper development and growth an imperative part of
development (Felber et al., 2013; Brown, 2014). Skeletal muscle develops in stages,
which together form a process known as myogenesis. Myogenesis begins during
embryogenesis with the migration of somatic mesoderm progenitor cells, which
terminally differentiate into myoblasts upon arrival at the various sites of skeletal muscle
formation (Bentzinger et al., 2012). These cells undergo stepwise proliferation,
differentiation, and fusion to form the polynuclear myofibers that make up skeletal
muscle (Mitchell et al., 2002). Initial development produces primary myofibers, which
become the scaffolding for subsequent skeletal muscle fibers. This occurs early on in
development and is typically completed halfway through the first trimester of pregnancy
(Sambasivan and Tajbakhsh, 2007). Late in the first trimester, secondary myofibers form
along these initial primary fibers but, unlike primary fibers, may not run the full length of
the developing muscle (Wilson et al., 1992). Early in the third trimester of pregnancy,
tertiary fibers appear around the existing primary and secondary fibers, completing the
myogenic process (Bentzinger et al., 2012). Together, these stages of myogenesis
(Figure 1-1) establish all myofiber populations before birth in most mammals, thus fiber
number remains static postnatal. Further growth occurs via fiber hypertrophy and requires
the incorporation of resident myoblasts to increase myonuclear content and nuclear
protein synthetic capacity as illustrated in Figure 1-1.
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Myogenic regulators of skeletal muscle growth
Throughout the myogenic process, the transcription factors shown in Figure 1-1
are expressed at specific stages, allowing this process to be tightly regulated. Initial
activation of myoblasts involves the expression of two paired-box (Pax) transcription
factors, Pax3 and Pax7, the latter of which acts as markers for these cells (Sambasivan
and Tajbakhsh, 2007; Bentzinger et al., 2012). Pax3 is critical for the migration and
establishment of the founder cell populations early in development, however it is not
exclusively expressed by skeletal muscle myoblasts (Bentzinger et al., 2012).
Alternatively, Pax7 is exclusive to myoblast populations and is responsible for
establishing satellite cell pools and secondary fibers during the later stages of
development and is one of the preferred markers for myoblast populations after birth
along with myogenic factor 5 (myf5) (Seale et al., 2000; Soto et al., 2017). These pools
of satellite cells are normally quiescent after birth acting as a reserve population capable
of proliferating after injury regenerating muscle in a process known as hypertrophy
(Morgan and Partridge, 2003). Terminal differentiation of myoblasts requires the
sequential expression of a series of transcription factors belonging to the basic-HelixLoop-Helix (bHLH) family: myogenic differentiation factor 1 (myoD), myf5, and
myogenin (Molkentin et al., 1995; Soto et al., 2017). Early in development,
dermomyotome cells mature into a primitive muscle structure known as the myotome,
which expresses high levels of myf5 followed by increased levels of myoD, marking
them as active muscle stem cells and initiating the transformation from stem cell to
muscle progenitor cells (Rudnicki et al., 1993; Bentzinger et al., 2012). The initial
expression of myf5 within these cell populations is typically coincident with the
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expression of Pax7 and proliferating cell nuclear antigen (PCNA) (Yates et al., 2014).
This expression profile marks these progenitor cells as active myoblasts destined for
proliferation and differentiation (Punch et al., 2009; Bentzinger et al., 2012). Terminal
differentiation of myoblasts during late gestation and postnatal begins with the onset of
myoD expression committing these myoblasts to differentiation (Brown, 2014; Yates et
al., 2014). As myogenin expression then increases, myoblasts begin to fuse and form the
myofibers that comprise skeletal muscle (Brown, 2014; Yates et al., 2014). Increased
myogenin expression causes differentiated myoblasts and myofibers to begin expressing
the type III intermediate filament known as desmin, which is responsible for the
structural development of the contractile unit of skeletal muscle called the sarcomere
(Paulin and Li, 2004). Both desmin and myogenin continue to be expressed by fetal
skeletal muscle throughout the gestational period and in postnatal skeletal muscle,
marking the continued fusion of myoblasts and myonuclear accumulation of myofibers
(Andrés and Walsh, 1996; Paulin and Li, 2004; Brown, 2014). Newly formed fibers also
begin to express myosin heavy chain (MyHC) isoforms, marking them as functional units
capable of contractile motion (Brown, 2014). MyHC help to further classify the muscle
fiber type and function within heterogeneous populations present in most skeletal
muscles, as discussed in the next section (Yates et al., 2016). Together, these
transcription factors and structural proteins serve as biomarkers for distinct stages of the
myogenic progression of myoblasts during development and postnatal during
hypertrophy (Figure 1-1).
Skeletal muscle growth late in gestation and postnatal must rely on existing
myoblast populations that reside adjacent to the muscle fibers and facilitate myofiber
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hypertrophy (Allen et al., 1979; Yates et al., 2014). During proliferation, a sub-population
of myoblasts does not differentiate or fuse to form fibers, instead becoming populations
of satellite cells, quiescent skeletal muscle stem cells (Morgan and Partridge, 2003).
These are present adjacent to muscle fibers between the sarcolemma and the endomysium
throughout the lifespan of the organism (Yates et al., 2014; Soto et al., 2017). Upon
injury, upregulation of muscle growth, mechanical activities such as exercise, or cell
death, satellite cells may become activated. Most newly-activated satellite cells then
proliferate and differentiate before fusing with existing muscle fibers, thus adding nuclei
and increasing protein synthesis capacity (Anderson et al., 2006; Brown, 2014). A subset
remains Pax7-positive/ myoD- negative and re-establish satellite cell populations in a
process known as self-renewal. Thus, populations of satellite cells are maintained by
asymmetric divisions and stored within the stem cell niche of the muscle itself, providing
the mechanism for growth of skeletal muscle fibers (Zammit et al., 2004; Jones and
Wagers, 2008; Yates et al., 2014). Myoblasts that commit to differentiation demonstrate
an increase in myoD expression (Bismuth and Relaix, 2010). High levels of myoD cause
myoblasts to exit the cell cycle, allowing most of the cells to differentiate (Zammit et al.,
2004; Brown, 2014). Subsequent upregulation of myogenin by myoD induces terminal
differentiation, whereby myoblasts become capable of fusing with myofibers (Brown,
2014; Yates et al., 2014; Soto et al., 2017). These two mechanisms allow for the
maintenance of the muscle stem cell pool, while also maintaining a readily available
source of satellite cells for muscle growth. The number of satellite cells present typically
decreases with age, making the proper development and size of initial populations crucial
to future skeletal muscle growth capacity (Morgan and Partridge, 2003; Brown, 2014).
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Perturbations in the establishment of this population during fetal development will have
lifelong negative consequences for muscle mass and the metabolic health of the
individual.
Skeletal Muscle Fiber Types, Metabolic Phenotypes, and Relative Abundances
Skeletal muscle in mammalian species have heterogeneous populations of skeletal
muscle fibers consisting of four different types, each with their own metabolic
phenotypes and contractile characteristics (Spangenburg and Booth, 2003; Yates et al.,
2016). Fiber type categories are defined by their metabolic phenotypes, twitch speed, and
strength of contraction upon stimulation (Schiaffino and Reggiani, 2011; Brown, 2014).
The proportions of fiber types within a muscle group can change over time based on the
influence that the environment or other extrinsic factors have on the metabolic, or
functional, demand of the muscle (Schiaffino and Reggiani, 2011; Yates et al., 2016).
Fiber types are identified by MyHC isoforms that are indicative of the fibers metabolic
activity, which can be broadly classified as either fast or slow twitch (Spangenburg and
Booth, 2003; Yates et al., 2016). Type I skeletal muscle fibers are the slow-twitch fiber
found throughout the body. These fibers are characterized by their red color due to the
high content of myoglobin and can be identified by expression of the MyHC-I isoform
(Schiaffino and Reggiani, 2011; Yates et al., 2016). Type I fibers exhibit high rates of
oxidative metabolism, increased mitochondria. and myoglobin content, larger nerve
terminals and motor endplate areas, a less developed sarcoplasmic reticulum, and higher
cytosolic free calcium (Schiaffino and Reggiani, 2011; Wang and Pessin, 2013). These
fibers favor oxidative phosphorylation as their primary metabolic pathway and, as their
name implies, contract slowly and generate less mechanical force relative to other fiber
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types (Spangenburg and Booth, 2003). Type I fibers are more fatigue resistant due to a
greater content of mitochondria and thicker Z lines, which mark the boundaries of
individual sarcomeres where thin actin fibers attach (Schiaffino and Reggiani, 2011).
Type II fast-twitch fibers can be delineated into three subgroups, which are Type
IIa, IIx, and IIb (Wang and Pessin, 2013). Type IIa fibers represent an intermediary
population between Type I and the other Type II fibers. These fibers are anatomically red
in color and maintain a higher content of mitochondria than other Type II fibers, relying
on both oxidative and glycolytic pathways to generate energy for their contractile force
(Schiaffino and Reggiani, 2011). Type IIa fibers can be distinguished from the other fasttwitch types by their high levels of succinate dehydrogenase (SDH) activity, the presence
of slow twitch motor units, and expression of MyHC-IIa (Spangenburg and Booth, 2003;
Schiaffino and Reggiani, 2011). In pigs and rodents, Type IIb fibers are anatomically
white in color due to the low amounts of mitochondria and myoglobin they contain. They
express the MyHC-IIb isoform (Schiaffino and Reggiani, 2011). These fibers are defined
as a fast-fatiguing, glycolytic populations that rely primarily on ATPase activity and
present with low levels of SDH activity (Schiaffino and Reggiani, 2011). They are
predominantly found in the lower extremities or hindlimbs and can generate a large
contractile force. They are quick to fatigue due to the low abundance of myoglobin and
capillary content (Spangenburg and Booth, 2003; Wang and Pessin, 2013). Humans,
cattle, sheep, and most other non-litter bearing mammals express the mRNA transcript
for Type IIb myosin but cannot produce the MyHC-IIb protein (Schiaffino and Reggiani,
2011). Type IIx fast-twitch fibers are an intermediary population of fibers that are instead
expressed by these mammals (Schiaffino and Reggiani, 2011). These fibers are
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anatomically white and rely on glycolytic metabolism to generate energy for contractile
force (Larsson et al., 1991). They have contractile shortening velocities similar to Type
IIa fibers, but present with less of ATPase and SDH activity and less resistance to fatigue
relative to Type IIa fibers (Larsson et al., 1991). Type IIx fibers are identified by their
expression of MyHC-IIx (Schiaffino and Reggiani, 2011). In addition to morphological
and contractile differences fiber types can also be categorized by their metabolic
phenotypes. Type I fibers demonstrate the greatest rate of insulin-stimulated glucose
uptake making them the most insulin-sensitive of the fiber types (Yates et al., 2016).
Type IIx fibers demonstrate the lowest insulin-stimulated glucose uptake rates with Type
IIa fibers representing an intermediate population between Type I and Type IIx myofibers
(Yates et al., 2016).
Skeletal Muscle Glucose Metabolism
Insulin regulation of skeletal muscle glucose utilization
Skeletal muscle accounts for approximately 40% of total body mass in most
mammals but it is responsible for upwards of 65% of total glucose consumption and 85%
of insulin-stimulated glucose metabolism (Felber et al., 2013; Brown, 2014). Glucose is
the primary source for energy production within skeletal muscle, and the maintenance of
homeostatic levels is primarily facilitated by insulin-sensitive skeletal muscle (Mizgier et
al., 2014). Systemic glucose consumption is regulated in part by the action of insulin,
with increased circulating levels associated with higher rates of glucose uptake into
skeletal muscle (Leney and Tavaré, 2009). Increased circulating blood glucose stimulates
the production and secretion of insulin from pancreatic β-cells, leading to inhibition of
hepatic gluconeogenesis and stimulation of glucose uptake by skeletal muscle for
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utilization or storage (Aronoff et al., 2004). Changes in uptake rates are facilitated by
insulin-dependent translocation of GLUT-4 transporters expressed by skeletal muscle,
which rapidly translocate from the cytoplasm to the plasma membrane following insulin
stimulation (Limesand et al., 2007; Leney and Tavaré, 2009; Pinto-Junior et al., 2018).
Skeletal muscle also expresses low levels of GLUT-1 transporters, which are
ubiquitously expressed throughout the body and operate in an insulin-independent
manner (Ebeling et al., 1998; Limesand et al., 2007).
Metabolic pathways for glucose utilization
Beginning in late gestation, increased blood glucose levels in the body lead to the
release of insulin, stimulating uptake of glucose by skeletal muscle (Hay et al., 1988).
After uptake, glucose can be utilized by a number of different metabolic pathways shown
in Figure 1-2. The relative activity of each pathway is dependent on the fiber type
composition of the muscle. Upon entry into the cell, glucose is converted to the metabolic
intermediate glucose-6-phosphate, which is then utilized via one of three major pathways
(Jensen and Richter, 2012). Initial formation of Glucose-6-phosphate (G-6-P) is mediated
by the enzyme Hexokinase II (HK2), an irreversible step in skeletal muscle (Petersen and
Shulman, 2002; Jensen and Richter, 2012). G-6-P can be stored as the polysaccharide
glycogen, providing the muscle with stores of energy that can be rapidly mobilized and
utilized later. Glucose utilized for immediate metabolization will undergo the process of
glycolysis. Glucose within this pathway is metabolized via a series of enzymatic
interactions to two 3-carbon pyruvate molecules (Bouché et al., 2004). This process
generates a relatively small amount of ATP and NADH (Bouché et al., 2004). Under
aerobic conditions, pyruvate will enter into the mitochondria where it is utilized in the
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TCA cycle to generate large amounts of NADH and FADH2. These high-energy electron
carriers are then utilized by the electron transport chain for oxidative phosphorylation
(Nelson et al., 2008). The process of oxidative phosphorylation is more time consuming
than glycolysis, however it represents a much more efficient use of glucose by producing
approximately 36 net ATP per glucose molecule compared to the approximately 2 net
ATP produced by glycolysis (Nelson et al., 2008). Under nutrient poor conditions such as
those experience by a PI-IUGR fetus, a large amount of pyruvate will instead be
metabolized into lactate (Bouché et al., 2004). Unlike glucose, lactate can then be
secreted by skeletal muscle to help maintain energy substrate levels within the body
(Bouché et al., 2004). Lactate excreted from skeletal muscle can travel to the liver, where
it is reformed into glucose via gluconeogenesis in a process called the Cori cycle (Cori,
1931). Lactate can also be utilized by cardiac muscle as a source of energy under nutrient
or oxygen restricted conditions (Kemppainen et al., 2002). A reduction in glucose
oxidation coincident with an increase in the less efficient glycolytic lactate production is
commonly associated with increases in adrenergic and inflammatory activity. It is also a
characteristic of individuals with metabolic syndrome (Bouché et al., 2004; Limesand et
al., 2007; Cadaret et al., 2017).
Metabolic regulation by insulin and IGF-I pathways
Insulin is the primary regulator of blood glucose concentrations. This protein
hormone is secreted by the β cells located in the islets of Langerhans within the pancreas
(Fu et al., 2013). Pancreatic β cells sense changes in blood glucose concentrations and
release insulin in corresponding amounts to maintain homeostatic levels within the blood.
Tissues and organs with high energy requirements, such as skeletal muscle rely on
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glucose as their primary source of energy and skeletal muscle stores it as glycogen for
rapid metabolism during periods of high energy output (Horowitz et al., 2001; Mizgier et
al., 2014). The insulin signaling cascade for skeletal muscle is shown in Figure 1-3. First,
insulin binds to its tyrosine kinase receptor, leading to the phosphorylation of the
downstream docking proteins, insulin receptor substrates (IRS) (Krook et al., 2000). IRS1 and IRS-2 are the primary types found in skeletal muscle (Krook et al., 2000; Boucher
et al., 2014). Their phosphorylation by IR leads to the activation of the key signaling
mediator phosphatidylinositol 3-kinase (PI3K) (Krook et al., 2000; Sarbassov et al.,
2005). PI3K is responsible for the transmitting activation signals of multiple pathways
involved in glucose transport and metabolism within skeletal muscle. The canonical
PI3K-mediated pathway is the activation of 3-phosphphoinositide-dependent protein
kinase 1 (PDK-1) and its subsequent phosphorylation of the AGC protein kinase family
including Akt1, p70 ribosomal S6 kinase (S6K), and protein kinase C (PKC) (Pearce et
al., 2010). Phosphorylation of Thr308 leads to the partial activation of Akt1, which is a
key mediator of metabolism within skeletal muscle (Sarbassov et al., 2005). This initial
phosphorylation leads to the translocation of Akt1 to the plasma membrane (Dan et al.,
2016) where further activation occurs by the additional phosphorylation of a serine
residue (S437) by the mammalian target of rapamycin (mTOR) complex-2 (Sarbassov et
al., 2005; Dan et al., 2016). Activation of Akt inhibits protein degradation by inactivating
forkhead box O (Foxo) via phosphorylation and also stimulates glycogen and protein
synthesis within skeletal muscle (Sano et al., 2003; Boucher et al., 2014). Akt also
stimulates glucose uptake via activation of the mammalian target of rapamycin complex 1
(mTORC1) and increases lipolysis via phosphorylation of peroxisome proliferator
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activated receptor gamma coactivator 1-alpha (PGC-1⍺) (Takaishi et al., 1999; Sano et
al., 2003; Düvel et al., 2010; Boucher et al., 2014).
Insulin-like growth factors (IGF-I, IGF-II) along with growth hormone are the
primary mediators of tissue growth and differentiation (Dupont and LeRoith, 2001;
Boucher et al., 2010). However, studies have demonstrated that these are pleiotropic
hormones with differing tissue-specific effects (Baker et al., 1993; Westwood et al.,
2001). Similar to insulin, binding of IGF to their tyrosine receptor complexes leads to the
activation of downstream signaling cascades, beginning with the phosphorylation of IRS,
which then activates the PI3K-Akt1 pathway (Boucher et al., 2010). Although they utilize
similar pathways as insulin downstream of receptor binding, IGF-I and II stimulate a
wide range of cellular functions associated with growth and differentiation distinct from
those of insulin (Coolican et al., 1997; Boucher et al., 2010). IGF-II is implicit in
development and growth of the placenta, and IGF-I concentrations in fetal blood are
directly correlated with in utero growth and birthweight (Brice et al., 1989; Ogilvy-Stuart
et al., 1998). However, the downstream activation of mTORC1 and FoxO3 mediated
pathways is still achieved by IGF-receptor binding. This elicits insulin-like effects on
protein cycling and glucose metabolism, suggesting that IGFs work synergistically with
insulin (Di Cola et al., 1997). Normal signal transduction of insulin and IGF pathways
(Figure 1-3) is crucial for fetal skeletal muscle growth, fetal development, and
metabolism (Rosenthal and Cheng, 1995; Thorn et al., 2011).
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The Immune System
Hematopoiesis and Fetal Development
Like myogenesis, the development of the immune system is a highly-ordered
process that occurs in progressive stages throughout gestation (Pagenkemper and
Diemert, 2014). Hematopoetic stem cells (HSC) begin developing in the yolk sac early in
embryogenesis, with the first functional cells appearing late in the first trimester of
pregnancy (Mikkola et al., 2006). The definitive origins of HSC populations remains
unclear, but functional populations can be detected within the yolk sac,
aortagonadmesonephros region (AGM), and placenta by the end of the first trimester
(Ciriza et al., 2013). The placenta plays a critical role in the development of HSC by
facilitating rapid expansion and even in situ generation of new cells (Mikkola et al.,
2006). This occurs during mid-gestation in mice with an almost 15-fold increase in HSC
numbers compared to the AGM populations (Mikkola et al., 2005; Mikkola et al., 2006).
Regardless of their site of origin, the fetal liver is the main site of expansion and
differentiation of HSC before they migrate to their respective immunological organs
(Ciriza et al., 2013). Immunological cells and their products are scarce in early
development to avoid premature activation and allow for these cells to mature during
development (Ygberg and Nilsson, 2012). High intrauterine production of proinflammatory cytokines can be associated with growth restriction and, if severe, abortion
(Ygberg and Nilsson, 2012). However, both naive innate and adaptive immune cells are
present in appreciable amounts by birth (Ygberg and Nilsson, 2012; Simon et al., 2015).
After birth, the cells of the immune system and all of the cellular elements of
blood arise from progenitor cells in the bone marrow termed pluripotent hematopoietic
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stem cells (pHSC) (Janeway Jr. et al., 2001). Innate and adaptive immune responses
depend on the activities of leukocytes, which facilitate the complex interactions between
these two overlapping arms of the immune system. Together, these two evolutionarily
conserved systems coordinate to protect the body from infectious agents, confer lifelong
immunity, and serve as a robust defense to the wide range of pathogenic microorganisms
present in the postnatal environment (Janeway Jr. et al., 2001).
The Innate Immune Response
The majority of cells in the innate immune system shown in Figure 1-4, arise
from a pHSC-derivative population of progenitors known as the common myeloid
progenitors (CMP) (Janeway Jr. et al., 2001). The skin and mucosal epithelia also provide
an additional first line of defense against infection and are considered to be part of this
system (Gleeson et al., 1982; Nikolovski et al., 2008). CMP-derived progenitor cells
termed granulocyte/macrophage progenitor cells (GMP) form the entire population of
innate immune cells with the exception of lymphoid progenitor-derived natural killer
(NK) cells (Janeway Jr. et al., 2001). Most leukocytes within the innate immune system
perform phagocytosis, the process of engulfing pathogens (Janeway Jr. et al., 2001).
These are identified via cell-surface pattern recognition receptors such as the members of
the toll-like receptor family (TLR), which serve to bridge the gap between innate and
adaptive immune responses (Alberts et al., 2002). This group of cells is collectively
known as phagocytes and act as a non-specific defense against pathogens via recognition
of pathogen associated molecules (PAMP) (Alberts et al., 2002). The subpopulation of
phagocytes known as monocyte/macrophages are involved in metabolic regulation via
interactions with endocrine pathways involved in metabolism (Alberts et al., 2002;
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Cadaret et al., 2017). Macrophages are tissue resident phagocytes that play a critical role
in pathogen recognition and inflammatory modulation (Meshkani and Vakili, 2016;
Cadaret et al., 2017). Monocytes are circulating populations of bone marrow derived cells
that patrol the lymphatic and circulatory system (Alberts et al., 2002). After recruitment
to sites of infection or inflammation, monocytes infiltrate tissue and become
macrophages, leading to the combined terminology monocyte/macrophage (Alberts et al.,
2002). Together with dendritic cells (DC), monocyte/macrophages represent a critical
link between the innate and adaptive immune systems by acting as professional antigen
presenting cells (APCs) (Alberts et al., 2002). APC are responsible for presenting
processed epitopes in the presence of co-signaling factors such as major
histocompatibility complexes I and II (MHC-I/II) to naïve T-cells (Triozzi and Aldrich,
1997; Oehler et al., 1998; Alberts et al., 2002). This MHC-I/II signaling cascade leads to
the activation of the adaptive immune component and a conserved antigen-specific
immune response. Monocyte/macrophage activity, TLR signaling pathways, and central
signaling vis NF𝜿B are universal to all host’s innate defense system (Janeway et al.,
2001a). The conservation of these pathways across mammalian species, vertebrates, and
many non-vertebrates allows research on these critical pathways to be applied to most
species.
The Adaptive Immune Response
Unlike the innate immune response, the adaptive immune system (Figure 1-4) is
specific to particular pathogens (Alberts et al., 2002). It is responsible for the clearance of
cells presenting processed PAMP and for long-lived protection against future infection by
specific pathogens (Janeway Jr. et al., 2001; Alberts et al., 2002). The two major cell
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types involved in adaptive immunity are T-cells and B-cells, collectively classified as
lymphocytes (Janeway et al., 2001b). Lymphocytes arise from the common lymphoid
progenitor (CLP) within bone marrow where B-cell maturation also occurs (Janeway Jr.
et al., 2001). Alternatively, T-cells migrate to the thymus before maturation can occur
(Zinkernagel, 1978). The differences in maturation sites give rise to the differential
classification. The adaptive immune system relies on clonal selection (CST), a theory
first posited in the early 1950s by Drs. Burnet and Talmage (Talmage, 1957). Mammals
and some non-mammalian species, first generate a large and diverse population of
lymphocytes that undergo commitment within primary lymphoid organs (Talmage,
1957). These cells then undergo rapid clonal expansion upon activation by a particular
antigen specific to their cell surface receptor (Talmage, 1957; Alberts et al., 2002). Since
its initial introduction, CST has been adapted to fit more recent findings regarding the
response and development of lymphocytes. These include the phenomenon of somatic
hypermutation in B-cell populations and self/non-self tolerance (Silverstein, 2002).
T-cell populations can be separated into two categories, which together comprise
the cellular response of the adaptive immune system (Janeway Jr. et al., 2001). Cluster of
differentiation 8 (CD8)-positive cells known as cytotoxic T-cells facilitate the destruction
of infected non-self cells and contribute to the memory response (Busch et al., 1998).
CD4-positive T-cells are called helper T-cells and can be sub-categorized by their
cytokine expression profiles and roles within the immune system into Th1, Th2, Th17,
and Treg populations (Zhu et al., 2010). This diverse population of cells mediates a
number of critical functions of the immune system, such as B-cell antibody production,
CD8+ activity, macrophage regulation, orchestration of systemic immune response,
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suppression of the immune response, and regulation of the magnitude and length of the
immune response (Mosmann et al., 1986; Zhu et al., 2010). Activation of naive CD4+ and
CD8+ populations requires a co-stimulatory MHC/ T-cell receptor (TCR)-dependent
signal from the above professional antigen-presenting cells. However, once memory cells
have been generated, they can be directly activated by their respective antigen. Similar to
innate immunity, the adaptive immune response is conserved across vertebrate species
(Flajnik and Kasahara, 2010).
Cytokines and Chemokines
The immune and inflammatory response is tightly regulated and diverse. Cells can
elicit differential effects based on location within the body, type of activation signal, and
acute vs. chronic responsivity (Janeway Jr. et al., 2001). The precision of inflammatory
responses are controlled in large part by extracellular mediators known as cytokines and
chemokines (Turner et al., 2014). These chemical messengers allow small numbers of
immune cell types to mediate a diverse and complex systemic immune response (Lata
and Raghava, 2008). Upon binding, cytokines and chemokines stimulate subsequent
intracellular signaling mechanisms modulating acute or chronic inflammation (Lata and
Raghava, 2008; Turner et al., 2014). Furthermore, changes in the expression profiles of
these signaling molecules have been implicated in stress responsivity, depression and
anxiety, and pathologies like type II diabetes and metabolic syndrome (Sassoon et al.,
1988; Vogelzangs et al., 2016; Akash et al., 2018; Yates et al., 2018).
Cytokines are small secreted proteins that serve as the chemical messengers for
the immune system. They have the ability to mediate systemic and local inflammation,
hematopoiesis, and immune responsivity (Lata and Raghava, 2008). Cytokines are
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canonically categorized as pro-inflammatory or anti-inflammatory, but recent studies
have demonstrated that cytokines can have pleiotropic effects depending upon the target
receptors they bind, and external co-signaling factors like glucocorticoids and growth
factors (Al-Shanti et al., 2008; Muñoz-Cánoves et al., 2013; Morey et al., 2015).
Generally accepted pro-inflammatory cytokines include the interleukin-1 (IL-1) family,
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF⍺), and interferon gamma (IFN𝛾)
(Turner et al., 2014). These cytokines signal via specific receptors that are responsible for
signal modulation and downstream effects (Figure 1-5). The major anti-inflammatory
cytokines are interleukin-4 (IL-4), interleukin-10 (IL-10), and the pleiotropic IL-6
(Cassatella et al., 1993; Muñoz-Cánoves et al., 2013). Similar to the inflammatory
cytokines, anti-inflammatory cytokines signal via specific families of receptors with
different downstream effects based on the cell type and context of activation (Ho et al.,
1993; Nelms et al., 1999) as shown in Figure 1-5. Dysfunctional expression of cytokines
has been implicated in the development of pathologies such as anxiety, depression, and
type II diabetes (Vogelzangs et al., 2016; Akash et al., 2018).
Chemokines are a conserved subset of cytokines primarily responsible for the
recruitment of circulating effector leukocytes (Moser et al., 2004). They also play roles in
immunological surveillance and in leukocyte development (Moser et al., 2004).
Chemokines are categorized broadly into two groups; chemotactic or homeostatic
(Constantin et al., 2000). Similar to cytokines, chemokines are also dual-functional and
create increasing gradients to recruit leukocytes within circulation to their target
(Constantin et al., 2000; Turner et al., 2014). Chemokines and chemokine receptors
(Figure 1-5) are critical for the tissue-specific responsivity of the immune system, as well
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as proper growth and development of tissues. (Turner et al., 2014; Quinn et al., 2017).
The best characterized chemokine in mammals is the pro-inflammatory interleukin 8, also
known as CXCL8 (Hammond et al., 1995). Similar to its pro-inflammatory cytokine kin,
it signals via activation of two different G-protein coupled receptors (GPCRs),
responsible for the recruitment of leukocytes to sites of inflammation and acts as an
angiogenic factor in humans (Hammond et al., 1995; Heidemann et al., 2003) (Figure 15). Chemokine Receptor 4 (CXCR4) and its ligand (CXCL12) have been shown to play a
role in placental growth as well as vascular development in the growing fetus
demonstrating the pleiotropy of these signaling molecules (Quinn et al., 2017).
Effects of Curcumin and Systemic Stress on Cytokine Regulation of Skeletal Muscle
Cytokines play a critical role in the regulation of tissues and organs throughout
the body including skeletal muscle, adipose tissue, and pancreatic β-cells (Andersson et
al., 2001; Al-Shanti et al., 2008; Hansen et al., 2010). Cytokine activity is coordinated by
circulating and tissue resident leukocytes and lymphocytes (Fan and Rudensky, 2016;
Holzlechner et al., 2017). Immune cells residing within the tissue possess the ability to
self-renew (Hashimoto et al., 2013), and differential expression of surface markers
delineate them from circulating immune cells, which are bone marrow derived
(Hashimoto et al., 2013). Meshkani & Vakili (2016) reviewed the literature showing that
tissue resident macrophages contribute to metabolic homeostasis and that abnormal
population profiles are associated with development of metabolic syndrome and type II
diabetes.

21
Tissue Resident Macrophages
A review by Martinez & Gordon (2014) concludes that tissue resident
macrophages are dynamic cells capable of differential activation depending on systemic
and local signals. Resident macrophages are categorized into two main phenotypes shown
in Figure 1-6. M1 macrophages are classically activated by IFN𝛾, Lipopolysaccharide
(LPS), TNF⍺, or granulocyte macrophage colony-stimulating factor (GM-CSF) (Chow et
al., 1999; Hansen et al., 2008; Kayagaki et al., 2013). TLR4-MyD88 signaling pathways
or inflammasome activation within these cells stimulates production of inflammatory
factors including TNF⍺, IL-6, IL-1β, CCL2, and CCL10 (Kayagaki et al., 2013; Martinez
and Gordon, 2014). M2 macrophages are considered to be alternatively activated by IL-4,
IL-10, glucocorticoids, and TLR signaling (Sironi et al., 2006). This population can be
further classified by activation signal and downstream effects into either M2a (IL-4
activated), b (TLR/IgG/Inflammasome complex activated), or c (IL-10 and
glucocorticoid activated) groups (Edwards et al., 2006; Sironi et al., 2006). Regardless of
initial activating signal, cells are associated with a predominantly anti-inflammatory
response. M2 populations are unique in their ability to recognize and respond at the
systemic level, while also being responsible for the local resolution of the inflammatory
response. It should be noted that these M0/M1/M2 macrophage phenotypes are dynamic
(Lavin et al., 2014). These classifications represent a snapshot of populations in a
constant state of flux as they respond to systemic and local signals during development
and after maturation (Lavin et al., 2014; Martinez and Gordon, 2014).
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Cytokine Regulation of Skeletal Muscle
Skeletal muscle growth, development, and function are regulated in part by
cytokine signaling (Spangenburg and Booth, 2003; Al-Shanti et al., 2008; MuñozCánoves et al., 2013). Recent studies in our lab demonstrate that cytokines affect both
insulin signaling and insulin-independent glucose metabolism within skeletal muscle
(Cadaret et al., 2017). Previous research demonstrates that skeletal muscle is capable of
secreting cytokines and growth factors in response to tissue injury, exercise, and other
stimuli (Pedersen and Febbraio, 2008). IL-6, TNF⍺, and IGF-I secreted by skeletal
muscle have since been recognized as myokines and represent a source of muscle growth
and metabolic regulation (Pedersen and Febbraio, 2008; Henningsen et al., 2010;
Schnyder and Handschin, 2015). Thus, skeletal muscle is a highly metabolic endocrine
organ capable of secreting a number of myokines with autocrine, paracrine, and
endocrine effects. Two multifunctional cytokine/myokines most commonly associated
with the regulation of skeletal muscle are TNF⍺ and IL-6 (Al-Shanti et al., 2008).
TNF⍺ is a pleiotropic cytokine with abnormal expression involved in
inflammatory skeletal muscle disorders and insulin resistance, and normal expression
essential for proper skeletal muscle development and growth (Al-Shanti et al., 2008;
Tüzün, et al., 2006). Abnormal TNF⍺ expression is commonly associated with the
pathology of type II diabetes, muscle wasting, and pro-inflammatory responses in skeletal
muscle (Li and Reid, 2000; Tüzün et al., 2006; Akash et al., 2018). Skeletal muscle
expresses tumor necrosis factor receptor 1 (TNFR1) and TNFR2 (Hsu et al., 1996). Most
inflammatory effects of TNF⍺ are due to activation of the NF𝜿B and JNK1 pathways by
TNFR1 signaling cascades (Figure 1-6), leading to the induction of inflammation,
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apoptosis, autophagy, and insulin resistance (Li and Reid, 2000; Plomgaard et al., 2005;
Yang et al., 2015). Activation of TNFR1 leads to the recruitment of adaptor proteins such
as tumor necrosis factor receptor-associated factors (TRAF), tumor necrosis factorassociated death domain (TRADD), and receptor interacting serine/threonine kinases
(RIPK) (Hsu et al., 1996). These adaptor proteins activate IKK, which induces NF𝜿B,
JNK1, and autophagy-associated pathways (Hsu et al., 1996; Criollo et al., 2010; Ting
and Bertrand, 2016). NF𝜿B and autophagy-associated pathway activation by TNFR1 is
dependent on TRAF2 (Puimège et al., 2014; Yang et al., 2015). Other downstream
pathways of TNFR1 affecting apoptosis and protein metabolism in skeletal muscle are
TRAF2-independent, signaling instead via TRADD-mediated pathways (Hsu et al., 1996;
Guttridge et al., 1999) The activation of NF𝜿B by TNF⍺ is context-dependent within
skeletal muscle and is involved in the regulation of cell survival and growth (Mourkioti
and Rosenthal, 2008a). TNFR1-mediated activation of the JNK1/AMPK pathways via
TRAF2 has similarly been shown to increase rates of mitophagy, autophagy, and reactive
oxygen species (ROS) production (Yan et al., 2012; Yang et al., 2015). Thus, TNF⍺mediated pathways play a multifaceted role in the development and growth of skeletal
muscle.
IL-6 is another pleiotropic cytokine/myokine that binds a membrane bound
receptor (IL6R) complexed with a homodimer of gp130 (Schroers et al., 2005). Studies
indicate that IL6R is only expressed in its membrane-bound form on hepatocytes and
leukocytes within the body in a classical manner (Keller et al., 2005; Wolf et al., 2014).
However, gp130 is expressed by almost every cell within the body (Schroers et al., 2005;
Wolf et al., 2014). These findings led to the discovery of a second soluble form of IL6R,
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termed sIL6R (Schroers et al., 2005). sIL6R complexes first with its ligand IL-6 and then
with a homodimer of gp130 (Schroers et al., 2005). The soluble version of IL6R is
produced via alternative splicing of mRNA in a number of cell types including skeletal
muscle (Keller et al., 2005; Wolf et al., 2014). This allows IL-6 to affect most cell types
via both classical and trans-signaling (Keller et al., 2005; Wolf et al., 2014). Classical
signaling is associated with the anti-inflammatory regenerative effects of IL6, and transsignaling has been implicated in the pro-inflammatory cascades that contribute to
autoimmune disease, metabolic dysfunction, and sepsis (Rose-John, 2012; Wolf et al.,
2014; Garbers et al., 2015). Activation of both receptor types leads to the association of
Janus kinases (JAK) JAK1 and JAK2 with gp130 (Figure 1-6) (Stahl et al., 1994). These
recruit signal transducer and activator of transcription (STAT)-1 and STAT3 to be
phosphorylated and translocated to the nucleus, where they up-regulate transcription of
genes involved in the IL-6 response (Hemmann et al., 1996). Inhibition of this pathway
occurs via negative feedback from JAK/STAT-induced suppressor of cytokine signaling3 (SOCS3), allowing the cell to return to its basal state (Babon et al., 2014). JAKmediated phosphorylation events can also activate the MAPK pathways and interact with
the PI3K pathway (Heinrich et al., 2003), which has multifunctional effects on skeletal
muscle. IL-6 produced during muscle contraction increases satellite cell proliferation in
adult skeletal muscle and prevents premature differentiation in developing myocytes (Sun
et al., 2007). However, IL-6 also interferes with IGF-1 signaling, increases age-related
muscle atrophy, and promotes some inflammatory disorders (Bartoccioni et al., 1994; De
Benedetti et al., 1997; Bonetto et al., 2012).
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Curcuminoid effects on skeletal muscle growth and cytokine signaling
Turmeric root, and its bioactive polyphenol curcumin represent a topic of
intensive research. A review of recent research by Hewlings & Kalman (2017)
summarizes how this extract of Curcuma longa plants may help manage inflammatory
and oxidative conditions. The anti-inflammatory effects of curcumin have been attributed
to its role as a NF𝜿B inhibitor (Mourkioti and Rosenthal, 2008b). The NF𝜿B pathway
can be activated by the inflammatory cytokine TNF⍺ to suppress myogenesis and
stimulate proteolysis promoting, loss of muscle protein (Mourkioti and Rosenthal,
2008b). However, it also enhances satellite cell proliferation and promotes cell survival
(Guttridge et al., 1999; Li and Reid, 2000; Mourkioti and Rosenthal, 2008b). Inhibition of
this pathway by curcuminoids may mediate some of the detrimental effects of cytokines
on skeletal muscle growth.
Stress-induced modulation of cytokine expression
Recent work has begun to assess systemic immunological responses to different
stressors and psychological pathologies. Reviews of this research indicate the differential
effects of stress type and magnitude on immune function, with differences in cytokine
secretion, antibody production, and cytokine expression pattern switching occurring in
circulating leukocytes (Padgett and Glaser, 2003; Morey et al., 2015). Circulating
leukocytes express glucocorticoid (GR) and catecholamine (ADR) receptors that upon
binding modulate the function of NF𝜿B, regulating cytokine production and gene
expression (Padgett and Glaser, 2003). Glucocorticoid (GC) binding to GR under high
stress conditions has been shown to modulate cytokine production by suppression of
NF𝜿B and downregulating pro-inflammatory cytokine gene expression, favoring a
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Th2/M2 anti-inflammatory phenotype instead (Reichardt et al., 2001). However, GC also
sensitize the innate immune system and upregulate inflammation through activation of
the NLRP3 inflammasome (Busillo et al., 2011). Furthermore, under periods of chronic
stress GR levels are decreased in part due to cytokine over-stimulation of the HPA-axis
(Liu et al., 2017). The catecholamines epinephrine (E) and norepinephrine (NE) modulate
immune function primarily through the actions of β2 adrenergic receptors (ADRβ2) and
the subsequent synthesis of cyclic-AMP (cAMP) (Reichardt et al., 2001). ADRβ2
appears to be preferentially expressed on Th1/M1 pro-inflammatory immune cells in
circulation and within tissues (Bellinger et al., 2008) Acute stimulation by
catecholamines leads to increased expression of inflammatory cytokines but has an
overall inhibitory effect similar to GCs (Bellinger et al., 2008). More recently, studies
have connected stress-induced cytokine expression and inflammation to behavioral
pathologies including anxiety and depression (Henry et al., 2008; Peng et al., 2012).
Together, this represents a promising new avenue of research regarding stress modulated
immunology, and its role in behavior. However, it is necessary to first understand the role
that inflammatory cytokines play in muscle growth and metabolic health outcomes.
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Chapter 2: Maternofetal inflammation at 0.7 gestation in ewes
leads to mild intrauterine growth restriction and impaired
glucose metabolism in offspring at 30d of age.
Abstract
Intrauterine growth restriction (IUGR) leads to lifelong deficits in growth of
offspring as well as an increased risk for metabolic disorders. These effects may be due in
part to intrinsic inflammatory system programming that occurs in response to chronic
exposure to stress in utero. Recent studies by our lab demonstrate that maternal
inflammation during either mid- or late-gestation induces an IUGR phenotype in fetal rats
and sheep, respectively. Turmeric root extract and its main polyphenol component
curcumin have antioxidant and anti-inflammatory properties. The objective of this study
was to determine whether sustained maternal inflammation at 0.7 gestation induces fetal
IUGR and programmed inflammatory system responses that persist in lambs at 30 days
of age, and whether these lead to deficits in growth and metabolism. We further sought to
determine whether these effects could be mitigated by daily oral curcumin
supplementation of the lambs. Timed-mated Polypay ewes were injected with bacterial
endotoxin (MI-IUGR) or saline (controls) on the 100th,104th,107th,110th, and 113th day of
gestational age (dGA; term~145 dGA). A subset of MI-IUGR lambs received a daily oral
supplement of curcumin mixed in piperine and corn oil (MI-IUGR+C), and all other
lambs received the piperine/corn oil carrier only. In MI-IUGR ewes, total white blood
cells (WBC) decreased (P < 0.05) immediately after each injection before subsequently
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increasing (P < 0.05). Rectal temperatures increased (P < 0.05) after each injection before
returning to normal, demonstrating a canonical inflammatory response. Lambs were
weaned 24 hours after birth. Birthweights of MI-IUGR lambs tended to be less (P < 0.1)
than controls, and females tended to be lighter (P <0.1) than males. Abdominal
circumference / body weight (BW) and cannon bone length / BW were greater (P < 0.05)
in MI-IUGR lambs at birth indicating asymmetric growth restriction. Day30 BW of MIIUGR lambs was less (P < 0.05) than controls, but MI-IUGR+C BW did not differ from
controls. MI-IUGR males tended to be lighter (P < 0.1) at 30d than males from the other
groups. Average daily gain (ADG) was less (P < 0.05) in MI-IUGR and MI-IUGR+C
compared to controls for males but not for females. Head circumference growth over the
30d period was greater (P < 0.05) in MI-IUGR and MI-IUGR+C females and less (P <
0.05) in MI-IUGR and MI-IUGR+C males compared to respective controls. Abdominal
circumference growth was greater (P <0.05) in MI-IUGR+C females and less (P<0.05) in
MI-IUGR+C males compared to controls. Brain weight / BW was greater (P < 0.05) in
MI-IUGR and MI-IUGR+C males compared to control males and was greater (P < 0.05)
in MI-IUGR males compared to MI-IUGR+C males, indicating persistent asymmetric
growth. Glucose-stimulated insulin secretion determined by square-wave hyperglycemic
clamp did not differ among groups. Hindlimb insulin-stimulated glucose oxidation was
less (P = 0.01) in MI-IUGR and MI-IUGR+C compared to control hindlimbs. Hindlimb
Insulin-stimulated glucose uptake did not differ among groups. Ex vivo primary skeletal
muscle glucose uptake was less (P < 0.05) in MI-IUGR muscle compared to control and
MI-IUGR+C. Ex vivo glucose oxidation was less (P < 0.05) in MI-IUGR and MIIUGR+C muscle compared to controls and was less (P < 0.05) in MI-IUGR lambs
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compared to MI-IUGR+C. Insulin increased (P < 0.05) ex vivo glucose uptake and
glucose oxidation (P < 0.05) in primary skeletal muscle in all groups. TNF⍺ increased (P
< 0.05) glucose uptake in MI-IUGR muscle. The results of this study demonstrate that
sustained maternal inflammation at 0.7 gestation caused fetal programming that affected
postnatal growth and glucose metabolism of MI-IUGR offspring. Future research to
determine what the mechanisms for inflammatory programming observed in MI-IUGR
offspring is warranted to understand how these inflammatory system changes arise and
contribute to the IUGR phenotype. Supplementation of curcumin in this study had
minimal effects on deficits in growth but was able to partially improve skeletal muscle
glucose oxidation. Further research is needed at different dosages, frequencies, and routes
of administration, as curcumin may represent a potential treatment for improving
metabolic outcomes in MI-IUGR offspring.
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Introduction
Intrauterine growth restriction (IUGR) leads to lifelong deficits in growth and
metabolic function of offspring, which increases risk for metabolic disorders (Hales and
Barker, 2013). Fetuses adapt to adverse in utero environments by repartitioning nutrients
to critical organs (i.e., brain, heart, lungs) and away from skeletal muscle (Yates et al.,
2012; Yates et al., 2018). This fetal programming is beneficial in utero but leads to
persistent reductions in muscle mass and glucose metabolism that prove detrimental to
glucose homeostasis in offspring (DeFronzo et al., 1981). Recent studies done by our lab
demonstrate that maternal inflammation during both mid- and late-gestation may induce
programmed inflammatory responses that impair muscle growth and glucose metabolism
in fetal rats and sheep (Cadaret et al., 2017; Cadaret et al., 2018). This could be due to
altered responsiveness of skeletal muscle to cytokines and other inflammatory changes
that disrupt insulin action and glucose metabolism (Cadaret et al., 2017; Cadaret et al.,
2018; Posont et al., 2018). Curcumin is the main bioactive polyphenol in extracts of the
root of Curcuma longa and has anti-inflammatory and anti-oxidative properties in
humans and animals (Hewlings and Kalman, 2017; Mariely Jaguezeski et al., 2018). The
bioavailability of curcumin alone is relatively low in the digestive tract, but is increased
by co-administration with piperine and corn oil (Jenkins and Fotouhi, 1990; Shoba et al.,
1998). We hypothesize that the maternal inflammation-induced fetal programming
responses we previously observed in MI-IUGR fetuses contribute to growth and
metabolic deficits in MI-IUGR offspring at 30d, and that supplementation with curcumin
may mitigate their effects. Therefore, the objective of this study was to determine if
sustained maternal inflammation induced by the administration of LPS during late-
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gestation produces MI-IUGR offspring and fetal programming responses that impair
growth and metabolism at 30 days after birth. We further sought to determine if daily oral
supplementation of curcumin could mitigate the effects on growth and metabolism in MIIUGR offspring.
Materials and Methods
Animals and Experimental Design
All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Nebraska-Lincoln. Studies were performed at the
University of Nebraska-Lincoln Animal Science Complex, which is an AAALAC
International accredited institution. Timed-mated Polypay ewes were treated (i.v.) with
saline (control, n = 8) or 0.1 µg/ kg BW of bacterial lipopolysaccharide (LPS; n = 12; E.
coli O55:B5; MilliporeSigma) in saline every third day from dGA 100 to 115 to produce
maternal inflammation-induced IUGR (MI-IUGR) lambs. Rectal temperatures were
recorded and complete blood counts (CBC, HemaTrue Veterinary Chemistry Analyzer,
Heska) were performed for total and differential white blood cell (WBC) concentrations
on blood samples collected at 0, 3, 6, 12, 24, and 48hr after each injection of LPS. After
vaginal birth, lambs were weighed and measurements were taken for head circumference
(HC), abdominal circumference (AC), crown-rump length (CRL), and cannon bone
length (CB). Lambs received colostrum within 12hr of brith. After 24 ± 2 hours, lambs
were weaned and transitioned to ad libitum milk replacer (DuMOR) prepared according
to manufacturer recommendations. Daily intake was recorded. Lambs were weighed daily
and body measurements were taken every week. Beginning at weaning a subset of MIIUGR lambs (MI-IUGR+C; n = 6) received daily oral supplement of curcumin (95%
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pure HPLC-verified; Bulk Supplements) mixed with commercial corn oil (1ml for first
three days, and 1.5ml after until necropsy at d30 ± 2) and 20 mg/kg BW of piperine (95%
pure HPLC-verified; Z-natural foods). All other lambs received corn oil and piperine
carrier only. At 25 ± 2 days, indwelling catheters and a perivascular blood flow probe
were surgically placed in hindlimb femoral arteries and veins as previously described
(Cadaret et al., 2018). Blood samples were subsequently collected daily from an arterial
catheter and CBC and blood gas, glucose, and lactate concentrations (ABL, ABL90
FLEX blood gas analyzer, Radiometer) were performed. Glucose-stimulated insulin
secretion (GSIS) and hyperinsulinemic-euglycemic clamp (HEC) studies were
performed at day 28 ± 2 and 29 ± 2 respectively. Lambs were euthanized at 30 ± 2 days
of age via a double barbiturate overdose. Organ weights were recorded and flexor
digitorum superficialis muscles were isolated for ex vivo metabolic studies.
Lamb GSIS Studies
β-cell function was determined using a square-wave hyperglycemic clamp
performed at day 28 ± 2 of age in control (n = 8), MI-IUGR (n = 6), and MI-IUGR+C (n
= 6) lambs as previously described (Yates et al., 2012; Camacho et al., 2017a). Three
baseline samples were collected at 5-min intervals prior to an intravenous dextrose bolus
(150mg/kg). This bolus was followed by continuous variable-rate infusion of 33%
dextrose solution targeting a steady-state glucose concentration of ~2-fold baseline value.
After 30 minutes of steady-state hyperglycemia three additional blood samples were
collected at 5-min intervals. Blood collected in EDTA syringes was centrifuged (14,000 x
g, 2min, 4ºC) to isolate plasma. Insulin concentrations were determined in duplicate via
ELISA (Ovine Insulin, Alpco). Intra- and inter-assay CV were 14.75% and 13.11%
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respectively. Samples collected in heparin-coated syringes were analyzed for blood gas,
glucose, and lactate using an ABL90 FLEX (Radiometer).
Lamb Hindlimb Glucose Metabolism Studies
Hindlimb-specific glucose utilization and oxidation rates at baseline and during
hyperinsulinemic euglycemic clamp (HEC) were determined in control, MI-IUGR, and
MI-IUGR+C lambs on day 29 ± 2 of age as described previously (Cadaret et al., 2018).
Lambs were first bolused (1mL, i.v.) with U-[14C]-glucose tracer (18.75 µCi/mL; PerkinElmer) prior to constant infusion (1ml/hr). Arterial and venous blood were collected
simultaneously at 5-min intervals (4 total draws) in heparin-coated syringes and EDTA
syringes after 40-min of infusion. Lambs were then bolused with glucose (150mg/kg) and
insulin (1500 mU; Humulin-R, Eli Lilly) before infusion (glucose, variable rate; insulin
500mU/mL, 5mL/hr) to produce stead state HEC. After HEC was achieved for 2hrs,
simultaneous venous and arterial samples were again collected at 5-min intervals as
described above. To measure glucose oxidation, whole blood (0.3mL) was added in
triplicate to micro-centrifuge tubes containing 2 M HCl and suspended inside a sealed 20mL scintillation vial containing 1 M NaOH. HCl facilitates the release of CO2 from
blood, which is then captured by the NaOH. After a 24-hr incubation at room
temperature, the micro-centrifuge tube was removed and UltimaGold scintillation fluid
(Perkin-Elmer) was added to each vial. Concentrations of 14C from each blood sample
was quantified using a Beckman-Coulter 1900 TA LC counter. Hindlimb glucose
utilization rate was calculated as the difference in glucose concentration between arterial
and venous samples normalized to the femoral blood flow rate and hindlimb weight at
necropsy. Glucose oxidation rates were quantified from the difference between venous
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and arterial 14C specific activities normalized to femoral blood flow rate and hindlimb
weight at necropsy. The amount of glucose oxidized in nmol was calculated from blood
14

C using the specific activity of the infused radiolabeled glucose.

Primary Skeletal Muscle Glucose Metabolism
Glucose uptake and oxidation was quantified in primary skeletal muscle from
control, MI-IUGR, and MI-IUGR+C lambs as previously described (Cadaret et al., 2017).
The flexor digitorum superficialis muscle of each lamb was collected tendon-to-tendon
and dissected longitudinally into ~800mg strips. Isolated flexor digitorum superficialis
muscles were washed in phosphate buffered saline (PBS; pH7.4) and pre-incubated for
1hr at 37ºC in Krebs-Henseleit bicarbonate buffer (KHB) containing no additives (basal),
insulin (5mU/mL Humulin-R), or tumor necrosis factor alpha (TNF⍺) (20 ng/mL;
MilliporeSigma). Muscle strips were then washed for 20-min in zero glucose treatmentspiked KBH. Glucose uptake was measured by incubating muscle strips in treatmentspiked KHB containing 1 mM [3H]2-deoxyglucose (300µCi/mmol) and 1mM [14C]mannitol (1.25µCi/mmol) for 20min. Glucose oxidation was measured by incubation in
treatment-spiked KHB containing [14C-U]D-glucose (0.25µCi/mmol) for 2 hrs, before
capturing 14CO2 in 1M NaOH for 2 hrs.
Serum Curcumin Quantification
Jugular blood draws were taken from MI-IUGR+C lambs 3hr after
supplementation with curcumin every third day after birth until the HEC was performed
at day 29 ± 2 of age. Blood collected in EDTA tubes (~1mL) was analyzed for WBC.
Blood collected in 3mL Heparin coated tubes (~2mL) was centrifuged (3,500 x g, 15
min, 4ºC) to isolate serum and stored at -80ºC. These samples were then sent to the
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Proteomics and Metabolomics Facility (PMF; UNL Center for Biotechnology Core
Facility) where the three bioactive curcuminoids curcumin, bisdemethoxycurcumin, and
demethoxycurcumin were measured using liquid chromatography with tandem mass
spectrometry (LC-MS/MS).
Statistical Analysis
All data were analyzed using the Mixed procedure in SAS (SAS Institute, Cary
NC) with lamb as the experimental unit. In vivo and ex vivo data were analyzed for
effects due to experimental groups, period (or incubation condition), and the interaction.
Period/condition was treated as a repeated variable. For in vivo metabolic studies,
samples within each period were averaged for each lamb. Similarly, technical replications
were averaged for each lamb in ex vivo studies. Morphometric and CBC data were
analyzed for effects due to treatment in maternal data and effects due to experimental
groups, sex, and the interaction in neonates. All data are presented as means ± SEM.
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Results
Maternal CBC Response
Maternal total WBC and differential WBC values for monocytes and granulocytes
decreased (P < 0.05) by 3 hr in MI-IUGR ewes after each LPS injection before increasing
(P < 0.05) by ~24hr and subsequently normalizing by ~72hr over the period between each
injection (Figure 2-1A, 2-1B, and 2-1C respectively). Differential WBC for lymphocytes
decreased (P < 0.05) by 3hr and normalized by ~24hr (Figure 2-1D) Rectal temperatures
increased (P < 0.05) by 3hr and normalized by ~9hr (Figure 2-1E).
Neonatal CBC Response
Neonatal total WBC and differential WBC values for monocytes and granulocytes
differed (P < 0.01) by day across all groups to varying degrees (Figure 2-2A, 2-2B, 22C, and 2-2D).
Lamb Growth Metrics
MI-IUGR (n=12) birthweight tended to be less (P < 0.1) than controls (n=8) but
cannon bone length/bodyweight and abdominal circumference/bodyweight was greater (P
< 0.05) than controls (Figure 2-3). In males, MI-IUGR (n=4) and MI-IUGR+C (n=3)
bodyweight tended to be less (P < 0.1) than controls (n=3) at 30d and MI-IUGR
bodyweight tended to be less (P < 0.1) than MI-IUGR+C males. At 30 days, abdominal
circumference/bodyweight and cannon bone length/body weight was greater (P < 0.05) in
MI-IUGR lambs than controls (Figure 2-4) and ADG, head circumference growth, and
abdominal circumference growth was less (P < 0.05) in MI-IUGR and MI-IUGR+C than
control males (Figure 2-5). In females, MI-IUGR (n=2) and MI-IUGR+C (n=3) head
circumference growth was greater (P < 0.05) than controls (n=5) and abdominal
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circumference growth was greater (P < 0.05) in MI-IUGR+C compared to both other
groups (Figure 2-5). Lung weight/ bodyweight was greater (P = 0.01) in MI-IUGR lambs
compared to controls and less (P= 0.01) in MI-IUGR+C lambs regardless of sex (Figure
2-6A) In males, brain weight/ bodyweight was greater (P < 0.05) in MI-IUGR and MIIUGR+C compared to controls and greater (P < 0.05) in MI-IUGR compared to MIIUGR+C (Figure 2-6B).
Glucose-Stimulated Insulin Secretion
GSIS studies did not reveal any significant differences between groups (Figure 27). Baseline hindlimb glucose uptake and oxidation rates did not differ between groups,
nor did plasma insulin.
Hindlimb Glucose Metabolism
Under HEC conditions, hindlimb insulin-stimulated glucose oxidation was less (P
= 0.01) in MI-IUGR and MI-IUGR+C lambs compared to controls (Figure 2-8). There
were no differences in hindlimb insulin-stimulated glucose uptake between groups.
Ex Vivo Primary Skeletal Muscle Metabolism
Glucose uptake by primary skeletal muscle from MI-IUGR lambs was less (P <
0.05) than that of control and MI-IUGR+C muscle (Figure 2-9A). MI-IUGR skeletal
muscle glucose uptake was increased (P < 0.05) by incubation with TNF⍺ compared to
basal. Incubation with insulin increased glucose uptake in all groups. In all media,
glucose oxidation rates were less (P < 0.05) in MI-IUGR and MI-IUGR+C muscle
compared to control muscle and in MI-IUGR skeletal muscle compared to MI-IUGR+C
skeletal muscle (Figure 2-9B). Insulin increased glucose oxidation rates in all groups.
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Discussion
The results of this study demonstrate that sustained maternal inflammation during
late gestation produces IUGR and fetal programming responses in skeletal muscle that
impair glucose metabolism in offspring at 30d. It further demonstrates that
supplementation of curcumin has minimal effects on growth deficits but may be able to
mitigate the changes in skeletal muscle glucose oxidative metabolism. MI-IUGR lambs
were smaller at birth than their control counterparts but had greater abdominal
circumference and cannon bone length to body weight ratios than controls, which is
indicative of asymmetrical fetal growth. At 30d, MI-IUGR lambs had greater abdominal
circumference and cannon bone length by bodyweight ratios and MI-IUGR males had
lower bodyweights compared to both control and MI-IUGR+C lambs, which indicate that
asymmetrical growth continues after birth in MI-IUGR lambs but is tempered by
supplementation with curcumin. Growth rates in males were slower in MI-IUGR lambs
receiving curcumin or placebo compared to controls, but growth rates in females did not
differ among groups. Consistent with asymmetrical growth, the brain and lung weights
relative to BW in all MI-IUGR males were greater than controls, but this size differential
was tempered when MI-IUGR were supplemented with curcumin. We previously found
that chronic maternal inflammation during late gestation leads to asymmetric fetal growth
rates (Cadaret et al., 2018), and the morphometric and organ spring differences observed
in the present study show that these intrinsic growth characteristics persist in the neonate.
Interestingly, female growth characteristics appeared to be less affected than males. Such
differences between sexes are not unprecedented as, recent studies have reported
differences between sexes in growth during early life in humans (Alur, 2019) and IUGR
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lambs (Hunter et al., 2015). This could represent a survival advantage in females after
periods of maternal stress and inflammation, but more research is warranted to
understand why this sex-specific dimorphism occurs and how it mitigates growth deficits
after intrauterine growth restriction in females.
Supplementation with curcumin had minimal effects on deficits in growth
characteristics in this study. If programmed inflammatory responses are indeed
contributing to the asymmetrical growth observed in MI-IUGR lambs, then this minimal
effect on growth may be due to the anti-inflammatory properties of curcumin. The
observed minor improvements and mitigation of asymmetrical growth characteristics in
this study could be due to curcumins ability to reduce inflammatory signaling pathways
in peripheral tissues and reduce circulating inflammatory cytokines (Hewlings and
Kalman, 2017). This would mitigate the effects of some of these inflammatory
programming responses on peripheral tissue growth characteristics and temper the growth
deficits as we observed in this study. This effect may instead be due to curcumins ability
to reduce serum free fatty acids, decrease blood glucose, and modulate the expression of
genes involved in lipoprotein metabolism in patients that suffer from metabolic
syndrome, which could lead to the alleviation of some of the nutrient repartitioning
inherent in asymmetrical growth (Na et al., 2013; Hewlings and Kalman, 2017). Thus, the
observed improvements in growth could instead be due to shifts in fatty acid metabolism
and reductions in serum free fatty acids which has been shown to improve insulin
resistance (Na et al., 2013), rather than alleviating the inflammatory responses that
contribute to the initial deficits in metabolism. This would instead involve shifts away
from the nutrient repartitioning responses that contribute to asymmetrical growth in
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IUGR-offspring by modulating fatty acid metabolism and transport allowing for some
minimal improvements in growth as we observed. Further research is clearly warranted to
determine how curcumin is able to mitigate some of the deficits in growth observed in the
current study and what mechanism are involved.
Glucose-stimulated insulin secretion was neither impaired by MI-IUGR
programming, nor improved by curcumin supplementation. These findings contrast with
the results of our fetal study using the same model for IUGR and indicate that lategestation sustained maternal inflammation induces conditions that suppress β-cell
function in utero but not fetal programming that impairs β-cell functional capacity after
birth. Previous studies using placental insufficiency to create IUGR have demonstrated
that impaired β-cell function and islet development is due to hypercatecholaminemia in
IUGR fetuses (Macko et al., 2016; Boehmer et al., 2017). These β-cell deficits persist in
the PI-IUGR born lamb (Camacho et al., 2017a). Adrenergic function was not measured
in the present study, but we would not expect changes in adrenergic function in a model
of maternal inflammation as these effects are due to a sustained inflammatory response
and are not likely to illicit the fetal stress response and hypercatecholaminemia observed
in models of placental insufficiency. Sustained MI-induced fetal programming did affect
glucose metabolism by altering hindlimb specific glucose oxidation and skeletal muscle
glucose utilization and oxidation. Fetal programming induced by our model may not be
detrimental to β-cell function as it failed to maintain dysfunction at measurable levels in
the absence of the restricted uterine environment, unlike the maternal hyperthermic
model for IUGR (Camacho et al., 2017a). Previous studies demonstrated that adrenal
demedullation improves functional insulin secretion in IUGR fetuses, but does not
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completely alleviate the metabolic deficits caused by IUGR and in fact further impairs βcell development (Davis et al., 2015; Macko et al., 2016). Thus, fetal programming
responses to maternal inflammation likely affect peripheral tissue responsiveness to
insulin rather than inducing β-cell dysfunction proper.
Insulin-stimulated hindlimb glucose oxidation rates were impaired in MI-IUGR
lambs compared to controls demonstrating the postnatal persistence of fetal programming
responses that change insulin responsivity of glucose metabolism and contribute to
metabolic dysfunction. Ex vivo studies showed that skeletal muscle that glucose uptake
was diminished in MI-IUGR neonates but was recovered by daily oral supplement of
curcumin. Skeletal muscle glucose oxidation was also impaired in MI-IUGR lambs but
was partially recovered by curcumin supplementation. These disparities among
experimental groups were observed under both basal and insulin-stimulated conditions.
Stimulation with TNF⍺ increased glucose uptake by MI-IUGR muscle but did not have
an effect on glucose uptake in skeletal muscle from either of the other two groups. Our
previous studies demonstrated that IUGR myoblasts and skeletal muscle have intrinsic
adaptations in inflammatory signaling pathways (Posont et al., 2018; Yates et al., 2018),
and TNF⍺ increases glucose uptake by acting as an insulin mimetic (Bach et al., 2013)
contributing to the pathogenesis of Type II diabetes (Plomgaard et al., 2005; Akash et al.,
2018). Increased glucose uptake when MI-IUGR skeletal muscle was stimulated with
TNF⍺ may reflect a similar condition. Regardless, it demonstrates that MI-IUGR skeletal
muscle responds differently to stimulation with TNF⍺. The recovery of normal glucose
uptake rates and improved oxidation rates associated with curcumin supplementation
suggest that curcumin mitigates deficits in skeletal muscle glucose metabolism. This may
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be due to its ability to promote insulin sensitivity in peripheral tissues possibly due to the
anti-inflammatory effects of this polyphenol, which could suppress inflammatory
pathways that have been previously implicated in the development of insulin resistance
(Plomgaard et al., 2005; Chen et al., 2015).
From the results of this study, we conclude that sustained maternal inflammation
during late gestation restricts fetal growth, yielding IUGR at birth. MI-IUGR lambs
develop intrinsic fetal programming that reduces growth and skeletal muscle glucose
metabolism at 30 days of age. These programmed changes likely contribute to the deficits
in growth and metabolic dysfunction observed in this and other studies. Females in this
study exhibited similar growth rates among all experimental groups, which may indicate
a possible survival advantage in this model of IUGR, as evidenced by their neonatal body
morphometrics compared to males. The mechanistic explanation for this sex-specific
advantage, however, is not clear from this study. The fetal programming response to
sustained maternal inflammation during late gestation did not produce the β-cell
dysfunction observed in other IUGR models or in fetal studies with this model, perhaps
due to a lack of fetal hypercatecholaminenia. Fetal programming to maternal
inflammation did produce changes in skeletal muscle responsivity to insulin that was
consistent with prenatal observations. Primary skeletal muscle from MI-IUGR lambs
demonstrated consistent deficits in glucose uptake and oxidation that were improved by
daily oral curcumin. Additionally, MI-IUGR skeletal muscle glucose uptake increased in
response to TNF⍺, suggesting that inflammatory programming previously observed in the
MI-IUGR fetus modulates skeletal muscle responsivity to cytokines. This represents one
example of a possible inflammatory adaptation that confers a survival advantage in utero
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but contributes to metabolic dysfunction after birth. Future research to determine the
mechanisms for inflammatory programming observed in MI-IUGR is warranted to
understand how they contribute to the IUGR metabolic phenotype. Supplementation of
curcumin in MI-IUGR offspring had minimal benefit on growth and whole-body
metabolism of lambs during the first 30 days of life. However, it appeared that curcumin
was able to improve glucose uptake and oxidation rates in skeletal muscle. Although
these results are encouraging, further research at different dosages, frequency, and routes
of administration will better determine the efficacy of curcumin as a treatment for
improving outcomes in MI-IUGR offspring.
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Figure 1

Figure 2-1. Total (A) and differential white blood cell counts for Lymphocytes (B),
Monocytes (C), and Granulocytes (D) and rectal temperatures (E) of pregnant ewes
injected with saline (control; n=8) or bacterial endotoxin (MI-IUGR; n=12) every
three days from 100-115 dGA. Arrows indicate injection time points and x-axis
values are time (hr) after first injection. * Mean differs (P < 0.05) from the mean of
the control group.
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Figure 2-2. Total and differential (Granulocyte, Monocyte, and Lymphocyte) white
blood cell counts for neonates.
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Figure 2-3. Lamb birthweight (A), measures of cannon bone length (B) and
abdominal circumference (C) by birthweight respectively in control (n=8; males=3,
females=5) and MI-IUGR (n=12; males=7, females=5) at birth. MI-IUGR lambs
weighed less than controls at birth, and demonstrated asymmetrical growth
restriction.
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Figure 2-4. Bodyweight (A), cannon bone length by bodyweight (B) and abdominal
circumference by bodyweight (C) at day30 in control (n=8; males=3, females=5),
MI-IUGR (n=6; males=4, females=2), and MI-IUGR+C (n=6; males=3, females=3)
neonates. MI-IUGR lambs weighed less than control and MI-IUGR+C lambs and
demonstrated asymmetrical growth characteristics.
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Figure 2-5. Average daily gain (A), Head circumference growth (B), and Abdominal
circumference growth (C) of control (n=8; males=3, females=5), MI-IUGR (n=6;
males=4, females=2), and MI-IUGR+C (n=6; males=3, females=3) neonates.a,b,c
Means with differing superscripts differ.
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Figure 2-6. Brainweight by bodyweight (A) and Lung by bodyweight (B) of control
(n=8; males=3, females=5), MI-IUGR (n=6; males=4, females=2), and MI-IUGR+C
(n=6; males=3, females=3) lambs. Lung by bodyweight was greater in MI-IUGR and
less in MI-IUGR+C lambs compared to controls. Brainweight by bodyweight was
greater in MI-IUGR and MI-IUGR+C lambs compared to controls.a,b,c,d,e Means
with differing superscripts differ.
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Figure 2-7. Plasma insulin concentrations (ng/mL) at basal and hyperglycemic states
and glucose/insulin ratio (mg/dL:ng/mL) during square-wave hyperglycemic clamp
in control (n=8), MI-IUGR (n=6), and MI-IUGR+C (n=6) lambs.
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Figure 2-8. Hindlimb-specific insulin stimulated glucose oxidation (A) and glucose
uptake (B) rates, respectively in control (n=8), MI-IUGR (n=6), and MI-IUGR+C
(n=6) lambs.
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Figure 2-9. Ex vivo primary skeletal muscle glucose uptake (A) and oxidation (B)
under basal, insulin-stimulated, and TNF⍺-spiked conditions in control (n=8), MIIUGR (n=6), and MI-IUGR+C (n=6) lambs. a,b,c Means with differing superscripts
report main effect of group and differ.
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Chapter 3: Changes in myoblast responsiveness to TNFα and
IL-6 and increased expression of autophagy-associated
pathway components contribute to intrinsic myoblast
dysfunction in intrauterine growth-restricted fetal sheep.

Abstract
Intrauterine growth restriction (IUGR) is linked to lifelong deficits in muscle
mass due to intrinsic functional deficits in myoblasts, but the underlying mechanisms for
this dysfunction are unknown. Inflammatory cytokines play a central role in regulating
myoblast function and muscle growth, and thus the objective of this study was to assess
the functional responsiveness of primary IUGR fetal myoblasts to TNFα and IL-6 in
culture and to examine potential changes in growth-regulating pathway components
during incubations with an IKK inhibitor (TPCA-1). Maternal hyperthermia was used to
induce placental insufficiency and produce IUGR fetuses (n = 7; thermoneutral controls,
n = 7) in pregnant sheep. Primary myoblasts were isolated from fetal skeletal muscle at
0.9 of gestation and their functional capacity was assessed after 3d in complete growth
media (20% FBS) that was un-spiked (basal) or spiked with TNFα (20ng/ml) in the
presence and absence of TPCA-1 (5µM), or spiked with IL-6 (1ng/ml) alone. A fetal
experimental group by culture media interaction was observed (P < 0.05) for myoblast
proliferation. Proliferation rates of IUGR myoblasts were less (P < 0.05) than control
myoblasts after 3d in basal or IL-6 spiked growth media but did not differ between
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groups in TNFα-spiked growth media. Growth media spiked with TNFα decreased (P <
0.05) proliferation rates in control myoblasts compared to their rates in basal media.
However, proliferation of IUGR myoblasts did not differ among basal, IL-6-spiked and
TNF-spiked media all of which were lower (P < 0.05) than control myoblasts in basal
media. Administration of TPCA-1 decreased (P < 0.05) proliferation rates in both control
and IUGR myoblasts compared to their respective rates without it. The magnitude of this
reduction was greater (P < 0.05) in IUGR myoblasts than in controls in both basal and
TNF⍺-spiked media. Fewer (P < 0.05) IUGR myoblasts were myogenin+ compared to
controls after 3-day incubation in basal, IL-6-spiked, or TNF-spiked differentiation media
(2% FBS). In both experiment groups, TNF-spiked differentiation media reduced (P <
0.05) myogenin+ myoblasts compared to basal and IL-6 spiked media. After 3d in basal
differentiation media, fewer (P < 0.05) IUGR myoblasts were desmin+ than controls.
However, desmin+ myoblasts did not differ between groups when cultured in IL-6-spiked
or TNF-spiked media. Differentiation media spiked with either cytokine reduced (P <
0.05) percentages of desmin+ myoblasts compared to basal media in controls but not in
IUGR myoblasts, as IUGR myoblasts exhibited low percentages of desmin+ cells in basal
media. mRNA expression for Toll-like receptor 4 (TLR4) was increased (P < 0.05) in
myoblasts from both fetal groups when differentiation media was spiked with TNFα but
to a greater (P < 0.05) extent in IUGR myoblasts than in controls. Expression for Tumornecrosis factor receptor 1 (TNFR1) and Unc-like kinase 2 (ULK2) was greater (P ≤ 0.05)
in IUGR myoblasts than in controls in all media types. Myoblast Interleukin 6 receptor
(IL6R) mRNA expression was not different between fetal groups or among media types.
Semitendinosus muscle collected from IUGR fetuses at the same time as myoblasts
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exhibited greater (P < 0.05) Interleukin 6 (IL-6) and TNFR1 mRNA expression, less (P <
0.05) IκB protein content, and greater (P < 0.05) c-Fos protein content than controls. We
conclude that multiple inflammatory pathways are enhanced in IUGR muscle/myoblasts,
which contributes to the diminished functional capacity of IUGR fetal myoblasts by
intrinsically altering their functional regulation. Furthermore, IUGR fetal adaptations
increased mRNA expression for key components of mitochondrial autophagy pathways
in myoblasts, which are important to cellular survival. Together, these mechanisms may
help to explain reduced muscle hypertrophy in the IUGR fetus.
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Introduction
Intrauterine growth restriction (IUGR) disproportionately reduces muscle mass in
fetuses and offspring (Padoan et al., 2004; Yates et al., 2014; Yates et al., 2018). We
recently found that IUGR fetal myoblasts exhibit intrinsic functional deficits (Yates et al.,
2016; Yates et al., 2018), but have not previously identified the underlying mechanisms
responsible for this dysfunction. Myoblasts are tightly regulated by inflammatory factors
(Paulin and Li, 2004; Yates et al., 2018), and programmed changes within this system
due to chronic intrauterine stress may represent one underlying molecular mechanisms
for impaired IUGR myoblast function (Yates et al., 2014; Cadaret et al., 2017). Tumor
Necrosis Factor-alpha (TNFα) and Interleukin-6 (IL-6) are potent multifunctional
cytokines involved in systemic and localized inflammatory responses (Tüzün et al.,
2006). We recently found that skeletal muscle mRNA expression for TNFR1 (TNFα
receptor) and IL6R (IL-6 receptor) were greater in near-term IUGR rat fetuses (Cadaret et
al., 2017). Both of these cytokines regulate myoblast proliferation and differentiation (AlShanti et al., 2008) and thus are essential factors in normal growth and development of
muscle. Therefore, we postulate that developmental changes in inflammatory regulation
of IUGR myoblasts contribute to their decreased functional capacity. In addition, the
IUGR fetal environment is characterized by nutrient restriction, hypoxia, and chronic
exposure to stress factors (Macko et al., 2016; Rozance et al., 2018). Recent studies have
implicated the activation of mitophagy and autophagy pathways in response to nutrient
deprivation and chronic stress as mediators of metabolic dysfunction and poor muscle
growth (Hosokawa et al., 2009; Yan et al., 2012). The Unc-51-like kinase 2 (ULK2)mediated activity of these pathways after initial activation by TNFα/TNFR1 signaling has
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been implicated in the pathology of Type II diabetes via mitochondrial dysfunction in
skeletal muscle (Yan et al., 2012; Yang et al., 2015). The activation of the I𝜿B kinase
(IKK) complex is a critical step in both the TNFα/TNFR1-mediated activation of NF𝜿B
signaling pathways, and in the induction of autophagy and mitophagy in skeletal muscle
(Karin, 1999; Mourkioti and Rosenthal, 2008c; Criollo et al., 2010). Thus, the objective
of this study was to determine whether programmed changes in inflammatory regulation
and in IKK mediated signaling pathways are responsible for the impaired functional
capacity of IUGR fetal myoblasts. We further sought to determine if these changes are
associated with changes in mRNA expression for key components of
mitophagy/autophagy signaling pathways.
Materials and methods
Animals and myoblast isolation
The following experiments were approved by the Institutional Animal Care and
Use Committees at the University of Nebraska-Lincoln and The University of Arizona
which are both accredited by AAALAC International. Columbia-Rambouillet ewes
purchased from Nebeker Ranch (Lancaster, CA, USA) and carrying singleton
pregnancies were used to create IUGR fetuses (n = 7). Placental insufficiency was
induced by exposing ewes to elevated ambient temperatures (40°C, 35% RH) from the
40th to the 95th day of gestational age (dGA), as previously described (Yates et al., 2014;
Yates et al., 2016). Control fetuses (n = 7) were from pair-fed ewes maintained at 25°C.
Ewes were euthanized and necropsied at 134 ± 1 dGA and myoblasts were isolated from
fetal hindlimb muscle as described (Yates et al., 2014). Briefly, fetal semitendinosus
muscles were dissected from the hindlimb of each fetus. Muscles were washed with cold
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PBS containing 1% antibiotic-antimycotic (AbAm; Gibco Life Technologies, Grand
Island, NY, USA) and 0.5% gentamicin (Gibco) before being finely minced and divided
into 50-ml tubes (~5 g tube-1). Minced muscle was then washed, re-suspended in PBS
containing 1.25 mg/ml protease type XIV from Strept. griseus (Millipore-Sigma, St
Louis, MO, USA), and digested at 37ºC for 1 hour to liberate myoblasts. After digestion,
samples were serial-centrifuged (500 x g, 10, 8, and 1 minute) and the supernatant was
collected and centrifuged (1500 x g, 5 minutes) a final time to pellet the isolated
myoblasts. Cellular pellets were re-suspended in DMEM (Gibco) containing 10% fetal
bovine serum (FBS, Atlas Biologicals, Ft Collins, CO, USA), 1% AbAm, and 0.5%
gentamicin and incubated for 2 hours (37°C; 95% O2, 5% CO2) to remove fibroblasts.
Purified myoblasts were grown in complete growth media (DMEM containing 20% FBS,
1% AbAm, and 0.5% gentamicin) on fibronectin-coated culture plates (10 µg ml-1;
Millipore-Sigma) for 24 hours, lifted from plates with Accutase (Gibco), re-suspended in
complete growth media containing 10% dimethyl sulfoxide (Millipore-Sigma), slowly
frozen, and stored in liquid nitrogen.
Myoblast functional studies
Myoblasts were quickly thawed at 37°C and pre-plated in DMEM containing 10%
FBS for 2 hours (37°C; 95% O2, 5% CO2) prior to treatment. To determine purity of
myoblast isolates, a subsample of cells were stained for the myoblast marker pax7 as
previously described (Cadaret et al., 2017), and isolates from all fetuses were ≥96%
pax7+. To determine proliferative capacity, myoblasts were plated at 5,000 cells well-1 on
fibronectin-coated 6-well culture plates, grown for 3 days in complete growth media, and
then incubated for 24 hours in complete growth media containing either no additive
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(basal), IL-6 (1ng/ml; Sigma) ,or TNFα (20ng/ml; Sigma) in the presence or absence of
the I𝜿B kinase inhibitor TPCA-1 (IKKi 5µM; ApexBio Technology, Houston, TX,
USA). Myoblasts were then pulse-labelled with EdU (10nM; Thermo Fisher), which is
incorporated into replicated DNA for 2 hours. Myoblasts were then cooled on ice for 2
minutes, lifted from plates with Accutase (Sigma), and fixed in suspension with 4%
paraformaldehyde (PFA; Millipore Sigma) for 10 minutes. To determine differentiation
capacity, a second set of myoblasts were plated at 20,000 cells well-1 as described above
and cultured for 3 days in differentiation media (DMEM containing 2% FBS, 1% AbAm,
and 0.5% gentamicin) that contained no additive (basal), 20ng/ml TNFα, or 1ng/ml IL-6.
After 3 days, cells were cooled, lifted from plates, and fixed in 4% PFA as described
above. All media were changed daily.
Immunocytochemistry
Proliferation rates were calculated as the percentage of myoblasts incorporating
EdU (i.e. undergoing DNA replication) during the 2-hour pulse period. These cells were
identified by staining for EdU in suspension using the ClickIT® EdU Alexa Fluor® 555
Cell Proliferation Assay Kit (Life Technologies) according to the manufacturer’s
recommendations. Briefly, fixed cells were incubated in 200 µL of a
permeabilization/blocking buffer comprised of PBS containing 1% bovine serum albumin
(BSA; Millipore Sigma), 2% FBS, and 0.5% Triton X-100 (Millipore Sigma) for 10
minutes at 4ºC. Cells were then pelleted by centrifuge (400 x g, 5 minutes) and resuspended in 100 µL of ClickIT® reaction cocktail prepared according to manufacturer’s
recommendations. After incubating at room temperature for 30 minutes, cells were
pelleted, washed twice, and re-suspended in Moxi Cyte Reagent (ORFLO Technologies,
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Ketchum, ID) for analysis. Differentiated myoblasts were identified by staining with
antiserum raised in the mouse against myogenin (F5B; 1:50; BD Pharmingen) or desmin
(DE-U-10; 1:250; GeneTex). Primary antibodies were diluted in permeabilization /
blocking buffer comprised of PBS containing 5% FBS, 0.5% Saponin (Millipore Sigma),
and 2% BSA, which was applied for 1 hour at room temperature. Afterward, myoblasts
were pelleted, washed, and incubated for 1 hour at room temperature with secondary
affinity purified anti-mouse IgG PE-Conjugate antibody (1:250; Cell Signaling). Cells
were then washed twice and re-suspended in Moxi Cyte Reagent for analysis. All
samples were analyzed on a zEPI flow cytometer (ORFLO Technologies), with gates set
from negative controls produced by incubating a subset of cells from each fetus in
permeabilization / blocking buffer containing no primary antibody.
RNA extraction and preparation
Transcript expression was measured in differentiated myoblasts from parallel
cultures performed for each fetus as described above and in samples of fetal
semitendinosus muscle collected and snap frozen at necropsy. Myoblasts were lysed on
the plate with 600 µl RLT buffer (Qiagen, Valencia, CA) and stored at -80ºC. Total RNA
from myoblast lysates and from homogenized skeletal muscle was isolated with the
RNeasy kit (Qiagen), including on-column DNase digestion with the RNase-Free DNase
set (Qiagen) according to manufacturer recommendations. To calculated RNA
concentrations and quality, isolates were analyzed on a Take3 plate with an Epoch
Spectrophotometer System (BioTek, Winooski, VT), and all samples produced a 260/280
ratio ≥ 2.0. Isolated RNA was reverse transcribed into cDNA using the QuantiTect
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reverse transcription kit (Qiagen). Samples were then diluted at 1:10 in RNase-free water
(Qiagen) and stored at -20ºC.
Gene expression
Primer design.
Primers and probes for analysis of myoblast gene expression were designed using
the Primer3 system (Untergasser et al., 2012), according to the recommended criteria for
use with ddPCR supermix for probe (No dUTP) based assays (Bio-Rad, Hercules CA,
USA). These were validated for target specificity using both National Center for
Biotechnology and Information primer design tools and the BLAT function of the UCSC
genome browser (University of California, Santa Cruz CA). Optimized sequences were
purchased as PrimeTime® probe assays from Integrated DNA Technologies (IDT;
Coralville, IA), re-suspended in IDTE buffer (IDT) to a stock concentration of 10X, and
stored at -20ºC. PrimeTime® probe assays were prepared using the recommended 10X
stock concentration protocol (IDT), yielding a final 1X concentration of 500 nM for each
primer and 250 nM for probes per reaction. For analysis of skeletal muscle gene
expression, oligonucleotide primers were synthesized as previously described (Tüzün et
al., 2006; Al-Shanti et al., 2008), and primer pairs were obtained from IDT. The complete
list of optimized primers and probes for each target gene is summarized in Table 3-1.
Myoblast gene expression.
Droplet digital PCR (ddPCR) analysis was performed in a duplex format by coamplifying the target gene of interest labelled with FAM and the housekeeping gene
ribosomal protein L19 (RPL19) labelled with HEX. Quantification was performed using
11 µl of a 2X concentration of QX200 ddPCR supermix for probe-based assays (Bio-
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Rad), yielding a final 1X concentration in each 22-µl reaction. Target gene primers and
master mix were added to individual wells of a colorless 96-well PCR plate (Sigma), and
100 ng of cDNA diluted in RNase-free water was added to individual wells to a final
volume of 22 µl. RNase-free water was used as the negative template control. Each
duplex was analyzed on an individual 96-well plate containing all fetuses and the
negative control. Mixtures were vortexed and centrifuged and approximately 20,000
droplets were generated using a QX200 Droplet Digital generator (Bio-Rad). Droplets
were transferred to a QX200 compatible ddPCR 96-well plate (Bio-Rad) and thermal
cycled on a C1000 Touch Thermo Cycler (Bio-Rad). Conditions were set according to
the pre-determined annealing temperatures of designed PrimeTime® assays. The plate
was then transferred to a QX200 Droplet Reader (Bio-Rad) and analyzed using
QuantaSoft Analysis Pro Software (Bio-Rad). Gene expression was determined in
duplicate for each sample.
Skeletal muscle gene expression.
PCR products were cloned into pCR II vectors (Invitrogen) and confirmed with
nucleotide sequencing by The University of Arizona Genetics Core as previously
described (Macko et al., 2016). Primer efficiency was determined, and standard curves
were produced using plasmid DNA. Expression for each gene of interest was determined
by qPCR using SYBR Green (Qiagen) with a 7900HT Real-Time PCR Detection System
(Life Technologies). Samples were initially denatured (95°C for 15 minutes) and then
amplified with 45 cycles of denaturing (96°C for 30 seconds), annealing (60–62°C for 30
seconds), and fluorescence measurement during extension (72°C for 10 seconds). Melt
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curves were performed after amplification to confirm product homogeneity. Gene
expression was determined in triplicate for each sample.
Western immunoblot
Intracellular protein concentrations for IκBα and c-Fos were determined in snapfrozen fetal semitendinosus muscle. Muscle samples (~100 mg) were homogenized in
200 μl of radioimmunoprecipitation buffer containing manufacturer-recommended
concentrations of Protease and Phosphatase Inhibitor (Thermo Fisher). Homogenates
were sonicated and centrifuged (14,000 x g for 5 minutes at 4ºC) to separate the
supernatant. Total protein concentrations were determined with a Pierce BCA Protein
Assay Kit (Thermo Fisher). Protein samples (35 μg) were boiled for 5 minutes at 95°C in
BioRad 4x Laemmli Sample Buffer and separated by SDS-polyacrylamide. These gels
were transferred to polyvinylidene fluoride low florescence membranes (BioRad) and
incubated in Odyssey block solution (Li-Cor Biosciences, Lincoln, NE) for 1 hour at
room temperature. They were then washed with 1X TBS-T (20 mM Tris-HCl, 150 mM
NaCl, 0.1% Tween-20). Membranes were incubated overnight at 4ºC with antiserum
raised in the rabbit against IκBα (1:200; Santa Cruz Biotechnologies, Dallas, TX) or cFos (1:200; Santa Cruz) and diluted in Odyssey block solution containing 0.05% Tween20. An IR800 goat anti-rabbit IgG secondary antibody (1:5000; Li-Cor) diluted in
Odyssey block solution with 0.05% Tween-20 and 0.01% SDS was applied for 1 hour at
room temperature. Blots were scanned on a Li-Cor Odyssey Infrared Imaging System and
analyzed with Li-Cor Image Studio Lite Software.
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Statistical analysis
Ex vivo myoblast function and mRNA expression data were analyzed for effects
due to fetal experimental group, culture media, and their interaction by ANOVA using
the Mixed procedure of SAS (SAS Institute, Cary NC, USA) with the repeated measures
function. The subject was fetus and the group was the fetal experimental designation. For
myoblast function, two technical replicates per incubation condition were performed and
averaged. Data for skeletal muscle mRNA and protein expression were analyzed by oneway ANOVA using the Mixed procedure of SAS. Myoblast mRNA expression analyzed
by ddPCR were calculated as the number of transcript copies of target gene per µl
normalized to the number of transcript copies of the reference gene RPL19 per µl.
Skeletal muscle mRNA expression data measured by qPCR were normalized to
expression of ACTB (β actin). Expression of both normalizer genes was steady between
groups and among media types. Values are expressed as means ± SE and fetus is the
experimental unit for all analyses.
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Results
Myoblast proliferation
A fetal group x media type interaction was observed (P < 0.05) for myoblast
proliferation rates (Figure 3-1). Proliferation was less (P < 0.05) in IUGR myoblasts
compared to controls in basal and IL-6 spiked media but did not differ between control
and IUGR myoblasts in TNF-spiked media. In control myoblasts, proliferation was
decreased (P < 0.05) after incubation in media spiked with TNFα compared to basal
media, but rates did not differ between basal and TNF-spiked media. TPCA-1 decreased
(P < 0.05) proliferation for both groups in basal and TNF-spiked media compared to
TPCA-1 free media. IUGR myoblasts incubated in the presence of TPCA-1 had
decreased (P < 0.05) proliferation compared to controls in both basal and TNF-spiked
media. Proliferation rates in IUGR myoblasts were similar among basal, IL-6, and TNFspiked media, and between basal and TNF-spiked media in the presence of TPCA-1.
Myoblast differentiation
The percentage of myogenin+ myoblasts from IUGR fetuses was less (P < 0.05)
than the percentage from controls regardless of the type of differentiation media (Figure
3-2). In myoblasts from both fetal groups, myogenin+ percentages were similar between
basal and IL-6 spiked media and were decreased (P < 0.05) in TNF-spiked media. A fetal
group x media type interaction was observed (P < 0.05) for desmin+ myoblasts (Figure 33). Percentages of desmin+ myoblasts were less (P < 0.05) for IUGR fetuses compared to
controls when incubated in basal media but did not differ between groups when incubated
in IL-6 or TNFα-spiked media. For control myoblasts, desmin+ percentages were greatest
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(P < 0.05) in basal media and least (P < 0.05) in TNFα-spiked media. For IUGR
myoblasts, desmin+ percentages did not differ among differentiation media types.
Myoblast mRNA expression
A fetal group x media type interaction (P < 0.05) was observed for TLR4
expression in differentiated myoblasts (Figure 3-4A). TLR4 expression was increased (P
< 0.05) in myoblast populations from both fetal treatment groups when incubated in
TNF-spiked media compared to basal media, but the increase in IUGR myoblasts was of
a greater (P < 0.05) magnitude than in controls. Myoblast mRNA expression for TLR4
was not different between fetal groups when incubated in basal or IL-6 spiked
differentiation media. Expression of TNFR1 was greater (P < 0.05) in differentiated
myoblasts from IUGR fetuses compared to controls regardless of differentiation media
type (Figure 3-4B). Similarly, the expression of ULK2 was greater (P < 0.05) in
myoblasts from IUGR fetuses compared to controls regardless of media type (Figure 34C). Myoblast mRNA expression for IL6R and USP25 did not differ between fetal
groups or among differentiation media (Figures 3-4D and E, respectively).
Skeletal muscle gene and protein expression
Expression for TNFA (TNFα) did not differ between control and IUGR fetal
semitendinosus muscles (Figure 3-5A). However, gene expression for IL6 and TNFR1
was greater (P < 0.05) in IUGR fetal semitendinosus than in controls (Figures 3-5B and
C, respectively). Semitendinosus content of IκBα protein was less (P = 0.05) in IUGR
fetuses compared to controls (Figure 3-6A). Conversely, semitendinosus content of c-Fos
protein was greater (P < 0.05) in IUGR fetuses compared to controls (Figure 3-6B).
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Discussion
In this study, we show evidence that IUGR fetal myoblasts may have inherently
greater responsiveness to the multifunctional effects of TNFα and IL-6, leading to
disruptions in their functional capacity to proliferate and differentiate. These findings
help to explain the impaired skeletal muscle growth previously observed in IUGR fetuses
(Yates et al., 2014; Cadaret et al., 2018). Incubation with TNF⍺ decreased ex vivo
proliferation, and both TNF⍺ and IL-6 decreased differentiation rates in control
myoblasts. However, IUGR myoblasts proliferated and differentiated at lower rates with
or without the addition of exogenous cytokines. Administration of an IKK inhibitor
resulted in decreased proliferation in all fetal myoblasts under both basal and TNF-spiked
conditions. This indicates inflammatory stimulation was enhanced even under basal
conditions. This effect was greater in IUGR myoblasts in both media. Moreover,
transcript expression patterns in IUGR myoblasts and semitendinosus muscle were
consistent with a change in their responsiveness to inflammatory factors, making them
more sensitive to the small amounts of endogenous cytokines either contained in the
serum-spiked media or produced by the cells themselves (Podbregar et al., 2013).
Enhanced sensitivity and immunomodulatory changes in these IUGR myoblasts may
provide the molecular mechanism to explain their previously observed intrinsic
functional deficits (Brown, 2014; Yates et al., 2014; Soto et al., 2017). These changes
could make IUGR myoblasts respond differently to IL-6 and TNFα-induced inhibition
even when the circulating and local expression levels are at resting concentrations.
Alternatively, these deficits might be due intrinsic adaptations within inflammatory
signaling pathways that render them less responsive to cytokines. A similar phenotype
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could manifest due to increased expression of survival elements downstream of NF𝜿B,
which has been previously shown to increase TNFR1 expression while simultaneously
counteracting its apoptotic signaling pathways (Puimège et al., 2014; Ting and Bertrand,
2016). If this is indeed the case, then the apparent enhanced sensitivity could be a
compensatory mechanism to maintain signaling function in the presence of increased
NF𝜿B signaling activation (Figure 3-7). This would reflect a survival-oriented signaling
response to cytokine stimulation, rather than an enhanced sensitivity to these
multifunctional signaling molecules. Indeed, when treated with an IKK inhibitor, both
control and IUGR myoblasts demonstrated decreased proliferation. IUGR myoblast
proliferation was less than controls in TNF-spiked media when IKKi was present
indicating that select TNF⍺ signaling pathways are altered in IUGR myoblasts to
possibly promote cell survival. Interestingly, our results also indicate that these two
cytokines had differing effects on normal myoblast differentiation. TNFα reduced
markers of early (myogenin+) and late (desmin+) differentiation in control myoblasts but
IL-6 reduced desmin+ myoblasts only, indicating that TNF⍺ may be a more potent
inhibitor of fetal myoblast differentiation than IL-6. Together, these findings show that
IUGR fetal conditions induce programming responses in skeletal muscle that may
modulate the inflammatory regulation of myoblasts, which diminishes their capacity to
function and facilitate hypertrophic muscle growth. These altered pathways may
represent key molecular mechanisms that help to explain the link between stress-induced
fetal adaptations and lifelong reductions in skeletal muscle mass in IUGR-born
individuals. Diminished proliferation rates in IUGR myoblasts incubated IKKi in TNFspiked media indicate that these cells rely in part on NF𝜿B-associated survival pathways
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to mitigate the effects of increased inflammatory signaling. However, further analysis of
alternative pathways with similar effects on proliferation and differentiation are needed to
identify how inflammatory modulation is altered in IUGR-born individuals.
Analyses of specific gene transcripts and proteins involved in canonical
inflammatory pathways show for the first time that intrinsic deficits in IUGR myoblasts
coincide with molecular changes that may enhance inflammatory signaling pathway
coupling. Fetal IUGR myoblasts and skeletal muscle exhibited increased mRNA
expression for the well-characterized inflammatory receptor TNFR1, which we postulate
augmented TNFα-associated action relative to controls despite similar TNFα
concentrations in culture media and similar skeletal muscle mRNA expression for TNFα.
The apparent enhancement of TNFα sensitivity was further supported by the greater
capacity for TNFα-spiked culture media to induce TLR4 expression in primary IUGR
myoblasts compared to controls. Greater TNFα/TNFR1 activity combined with the
potential for greater TLR4 activity represents a possible mechanism for increased
autophagy and mitophagy within IUGR myoblasts via activation of the IKK complex
(Fitzgerald et al., 2004; Criollo et al., 2010). As illustrated in Figure 3-8, IKK increases
activity of NFκB, a keystone of canonical inflammatory signaling, by facilitating the
ubiquitination and degradation of its arrest protein, IκBα (Karin, 1999). It also plays a
non-canonical role in stress-associated stimulation of autophagy/mitophagy pathways by
increasing ULK2, a key factor in nutrient deprivation-induced autophagy (Lee and
Tournier, 2011). Indeed, we observed that IUGR skeletal muscle contained reduced
amounts of IκBα and IUGR myoblasts exhibited greater gene expression for ULK2. We
further found that IUGR skeletal muscle had increased amounts of c-Fos, which is
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induced by TNFα (Haliday et al., 1991; Tu et al., 2013) and has been shown to impair
myoblast differentiation by interfering with myoD and myogenin (Li et al., 1992;
Trouche et al., 1993; Waskiewicz and Cooper, 1995; Rivard et al., 2000; Wozniak et al.,
2005). These observations indicate that IUGR fetal muscle expressed greater
inflammatory signaling activity despite the normally immunosuppressive in utero
conditions during pregnancy (McCracken et al., 2004), which would be consistent with
human studies showing greater inflammatory cytokine concentrations in cord blood
(Laskowska et al., 2006). The entirety of the changes that occur within these
inflammatory pathways has not been fully assessed, but the greater apparent activity of
these pathways was not associated with changes in expression of USP25, which mediate
both inflammatory responses and skeletal muscle differentiation (Bosch-Comas et al.,
2006; Zhong et al., 2013). Moreover, gene expression for the IL-6 receptor remained
unchanged between our fetal groups and among incubation conditions, although
expression for the ligand itself was increased in IUGR skeletal muscle. Thus, IL-6
signaling activity may have been increased by greater ligand gene expression, whereas
TNFα signaling activity was enhanced at the level of its receptor and downstream
signaling components. Nevertheless, it appears that enhanced TNFα/TNFR1 affected
NFκB-associated and NFκB-independent pathways downstream of IKK, as demonstrated
by reduced muscle IκB content and increased myoblast ULK2 gene expression,
respectively. These findings implicate adaptive changes in pathways downstream of IKK
associated with nutrient sensing, stress responses, and cellular survival in the
development of the IUGR phenotype (Limesand et al., 2009; Thorn et al., 2009) and a
molecular mechanism for reduced muscle mass and impaired skeletal muscle growth.
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Intrinsically-reduced proliferation and differentiation in IUGR myoblasts restricts
muscle growth, which is beneficial to fetal survival of intrauterine nutrient deprivation
and hypoxia but also predisposes offspring to metabolic health disorders (Yates et al.,
2012). Because cytokines play an essential regulatory role in muscle growth and
development (Djavaheri-Mergny et al., 2006; Limesand et al., 2007; Al-Shanti et al.,
2008), the adaptive mechanisms observed in this study may help to explain smaller
muscle fibers and reduced muscle mass in IUGR fetuses (Yates et al., 2014; Yates et al.,
2016), which in turn helps explain their impaired glucose homeostasis (Godfrey and
Barker, 2000; Cadaret et al., 2018). Although not measured in the present study, this is
could perhaps be due to the non-canonical activation of JNK/MAPK by TNFR1-mediated
activation of IKK pathways involved in the mitophagy of mitochondria in response to
cellular stress (Yan et al., 2012; Yang et al., 2015). TRAF2-mediated activation of
JNK/MAPK pathways by stress would explain increases in c-Fos (Fitzgerald et al., 2004;
Limesand et al., 2007; Brown et al., 2015) and its associated pathways that are implicit
regulators of myoblast-facilitated skeletal muscle growth (Li et al., 1992; Trouche et al.,
1993; Rivard et al., 2000). Furthermore, coinciding stimulation of survival-oriented antiautophagic pathways via canonical IKK-NFκB activation (Reid and Li, 2001; Yan et al.,
2012) may help to explain how muscle fiber size and oxidative metabolic phenotypes are
reduced without a loss in fiber numbers (Limesand et al., 2007; Yates et al., 2014; Brown
et al., 2015; Yates et al., 2016). In TNF-spiked media, IUGR myoblasts demonstrated
decreased proliferation rates when only when IKKi was added. This would indicate that
some level of IKK-associated signaling within these cells differs from controls allowing
them to proliferate at rates similar to control myoblasts in the presence of TNF⍺ in spite
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of an enhanced inflammatory signaling response. Increased ULK2 activity would further
contribute to IUGR-associated metabolic dysfunction, as increased autophagy and
mitochondrial degradation has been implicated in the pathogenesis of Type II diabetes
(Yan et al., 2012). These insights implicated the activation of mitophagy/autophagy
pathways by an altered inflammatory signaling response in the development of the IUGR
phenotype. This represents a promising avenue of further study to fully understand how
this complex interaction might be occurring, and whether it is indeed due to an enhanced
TNFR1 signaling system. Although TNFR1-associated signaling appears to be
responsible for initiating this response in our study, activation of the IKK pathway can
occur through a number of different signal transduction systems separate from
inflammatory signaling. If inflammatory responsiveness is indeed altered within IUGRmyoblasts then this increase in autophagy could represent a compensatory response to
increased NF𝜿B-mediated activity, which previous studies have shown TNFR1 signaling
to inhibit (Qing et al., 2007; Criollo et al., 2010). Thus, the observed increases in TNFR1
could be due to increased NF𝜿B signaling in the absence of altered canonical constitutive
TNFR1 signaling downstream of expression (Criollo et al., 2010; Puimège et al., 2014).
Alternatively this activation could be due to other, yet unidentified, pathways that are
differentially expressed within the IUGR phenotype downstream of IKK such as
increases in beta-adrenergic signaling pathways or hypoxic responses both of which have
also been implicated in the IUGR phenotype and activation of autophagic pathways (Yan
et al., 2012; Farah et al., 2014) It is worth noting that this outcome can be stimulated by
TNFα via TRAF2-mediated activation of JNK/MAPK pathways (Yang et al., 2015) and
by TLR4 via activation of the IKK complex (Reyna et al., 2008; Criollo et al., 2010).
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However, more robust studies need to be conducted to establish if these pathways
downstream of IKK are indeed differentially expressed in IUGR myoblasts, and to
determine what proteins and genes are responsible for this phenotype. The identification
of potential differential activation of autophagy/mitophagy-associated pathways
represents a novel avenue of further research, as we continue to attempt to identify the
adaptations that occur in IUGR-individuals.
Conclusions
Fetal adaptations that result from IUGR may alter the responsiveness of skeletal
muscle stem cells to inflammatory factors, especially cytokines. These programmed
changes, which mostly likely follow chronic inflammatory exposure and nutrient
restriction in utero, may also be linked to cellular autophagy/mitophagy pathways
associated with long-term nutrient deprivation. In IUGR myoblasts, changes were
observed in pathways associated with the pleiotropic cytokines TNFα and IL-6. These
changes appeared to increase pathway components associated with the anti-apoptotic
effects of IKK-mediated NFκB activation, pro-mitophaghic and autophagic effects via
ULK2 upregulation, and disrupted differentiation via c-Fos upregulation, all of which
help to explain reduced hypertrophy in IUGR skeletal muscle fibers without a reduction
in fiber number. Our findings in cultured IUGR myoblasts indicate that they could
possibly demonstrate altered inflammatory activity independent of their environment,
thus providing one potential molecular mechanism to explain their intrinsic dysfunction.
Together, our findings show that IUGR fetal skeletal muscle adaptations alter the
response of myoblasts to regulatory cytokines by possibly enhancing both canonical and
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non-canonical pathways involved in myoblast function, metabolism, and cellular
survival.
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Table 3-1. Primer and oligo sequences for ddPCR and qPCR.
Gene

Protein

Primer Sequence

Product
Accession Number
Size

ddPCR Primers
RPL19

60S Ribosomal
Protein L19

TLR4

Toll-like Receptor 4

TNFR1

TNFα Receptor 1

IL6R

IL-6 Receptor

ULK2

Unc51-like Kinase 2

USP25

Ubiquitin-specific
Peptidase 25

GCAGACAAGGCTCGCAAG
CTAACACAACAGCTGGGCAG
HEX-TGGCGTAAGTTCTGAGGCAT-ZEN/IB FQ
CAGATGCAGAGACCAACCCG
CACTGAACACACCCTGCATC
6-FAM-TCCACCTGAGGAGGAGAATC-ZEN/IB FQ
CACCCGCAAAATAGCACCAT
AGAGAAAGAAGCAGGGCCTC
6-FAM-CCAAGTGCCACAAAGGTAGG-ZEN/IB FQ
AACAGAGGCTACTTCTTCCCC
GGCAGTGAGGAGCGACTTAT
6-FAM-TAATGGGTAGGCCTAGCAGC-ZEN/IB FQ
CACCTGTTGCCTGTTCCATC
CTGACGGAACTGCTCAGGAA
6-FAM-TTCCTTCTCTCAGTGGGCAC-ZEN/IB FQ
ACCAAGGCATCACATGAGCA
ATCTCGTGAACATGGATGGGT
6-FAM-TGAAACAGTTTTGCAGTCGGT-ZEN/IB FQ

100

NC_019468.2

100

NM_001135930

100

NM_001166185

100

NC_019458.1

100

NC_019468.2

100

NC_019458.2

147

NM_001009784

120

NM_001009392

qPCR Primers
GCGGCATTCACGAAACTACC
CCAGGGCAGTGATCTCTTTCTG
TTCACAAGCGCCTTCAGTCC
TCTGCTTGGGGTGGTGTCAT

ACTB

β Actin

IL6

Interleukin 6 (IL-6)

TNFA

Tumor necrosis factor
α (TNFα)

CATCAAGAGCCCTTGCCACA
CGGCAGGTTGATCTCAGCAC

130

NM_001024860

TNFR1

TNFα Receptor 1

CTGGTGATTGTCTTTGGGCTTT
AGCGACATGCTAAAACCACAGA

61

NM_001166185
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Figure 3-1. Proliferation rates in primary IUGR fetal myoblasts incubated for 24
hours in complete growth media (20% FBS) containing no additive (basal), TNFα
(20 ng ml-1) in the presence or absence of TPCA-1 (5µM) or spiked with IL-6 (1 ng
ml-1) alone. Cells were pulsed with 10nM EdU for 2 hours. a,b,c,d means with
different superscripts differ (P < 0.05). N-value represents pairs of one IUGR and
one control animal’s isolated myoblasts.
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Figure 3-2. Percentages of myogenin+ primary IUGR fetal myoblasts after 4-day
differentiation in media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1
ng ml-1). Differences (P ≤ 0.05) were observed for main effects of fetal treatment and
differentiation media, but no interaction between these main effects was observed.
N-value represents pairs of one IUGR and one control animal’s isolated myoblasts.
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Figure 3-3. Percentages of desmin+ primary IUGR fetal myoblasts after 4-day
differentiation in media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1
ng ml-1). a,b,c means with different superscripts differ (P < 0.05). N-value represents
pairs of one IUGR and one control animal’s isolated myoblasts.
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Figure 3-4. Gene expression (ddPCR) for (A) TLR4, (B) TNFR1, (C) ULK2, (D)
IL6R, and (E) USP25 in primary IUGR fetal myoblasts after 4-day differentiation in
media containing no additive (basal), TNFα (20 ng ml-1), or IL-6 (1 ng ml-1). a,b,c,d
means with different superscripts differ (P < 0.05).
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Figure 5.

Figure 3-5. Gene expression (qPCR) for (A) TNFA (TNFα), (B) IL6 (IL-6), and (C)
TNFR1 in semitendinosus skeletal muscle from IUGR fetal sheep. * fetal treatment
means differ (P < 0.05).
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Figure 3-6. Protein content (western immunoblot) for (A) IκBα and (B) c-Fos in
semitendinosus skeletal muscle from IUGR fetal sheep. * fetal treatment means
differ (P < 0.05).
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Figure 3-7. Diagram of two hypothesized inflammatory programming responses that
lead to enhanced inflammatory signaling. A) Increased expression of TNFR1 leads
to increases in NF-𝜿B signaling via IKK activation. B) Increased intrinsic NF-𝜿B
signaling has a positive feedback effect on TNFR1 increasing expression and leading
to enhanced inflammatory responsivity.
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Figure 3-8. Integrated schematic of the hypothesized adaptive changes in IUGR fetal
skeletal muscle and myoblast signaling pathways that enhance the responsiveness to
cytokines, impair myoblast functional capacity, and increased autophagy and
mitophagy.
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Chapter 4: Blood gene expression of stress-responsive genes as
novel biomarkers for assessing stress and wellbeing in rodents
& exotic species.

Abstract
Sustained exposure to stress mediators like cytokines and catecholamines
ultimately leads to alterations in the cellular expression of their targets. Stressors like
maternofetal inflammation have been linked to the development of intrauterine growth
restriction (IUGR), which is associated with fetal growth and metabolic adaptations that
persist after birth. Our lab previously found that IUGR rat fetuses have increased plasma
TNF⍺ and evidence of changes in inflammatory stress responsivity. The objective in Exp.
1 was to assess inflammation-associated gene transcript changes in fetal and maternal
blood pellets from Sprague-Dawley rats injected daily with saline, bacterial
lipopolysaccharide (LPS) endotoxin, or LPS + the non-steroidal anti-inflammatory drug
(NSAID) meloxicam from the 9th day of gestation age (dGA) to the 11th (term = 21
dGA). Maternal samples collected at 0, 6, and 54 hr after onset of LPS injection and fetal
samples collected at necropsy on dGA 20, were assessed for TNF⍺, TNFR1, IL6R, Fn14,
and INFγR1 differential expression using ddPCR. Fetal TNFR1 tended to be greater (P <
0.10) after maternofetal inflammation (MI), but not when meloxicam was given
concurrently. Fetal IL6R was reduced (P < 0.05) by MI and was not rescued by
meloxicam. Maternal TNFR1 was increased (P < 0.05) by LPS at 6 hours and was not
ameliorated by meloxicam administration. No other gene transcripts differed among
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groups. Together, our findings demonstrate that maternofetal inflammation during midgestation leads to transient maternal changes and fetal adaptations in cytokine signaling
pathways, which are reflected in the transcriptome of circulating leukocytes. We further
show that changes were generally not alleviated by concurrent administration of
meloxicam. Given our findings in Exp. 1, the objective of Exp. 2 was to determine if
differential expression of stress-responsive genes in blood samples from zoo animals
analyzed via ddPCR could be potential stress biomarkers. Total RNA was extracted from
whole blood of cheetahs, elephants, and giraffes. The ability to measure mRNA for
TNF⍺, TNFR1, IL6R, IL6, IL10, ADRβ2, NR3C1 was assessed using ddPCR analysis.
RPP30, RPL19, and YWHAZ were assessed as potential normalizers. For elephant and
cheetah target transcript analyses, probes were designed using the assemblies published
on the National Center for Biotechnology Information (NCBI) database. Giraffes do not
have a published assembly available, so an cross-species technique was used to design
primers specific to segments of the target transcripts that were predicted to be highly
conserved among giraffe, cow, and sheep. In cheetahs (n=2), primers and probers were
successfully validated for ADRβ2, IL10, IL6R, NR3C1, TNFR1, TNF⍺, and all three of
our potential normalizers. However, only RPL19 had a relatively low calculated CV (7%)
and was thus presumed to be the most suitable for this species as a normalizer. In giraffes
(n=1), we successfully designed cross-species primers for TNF⍺ and ADRβ2, but not for
any of our other intended targets. In elephants (n=3), primers and probes were validated
for the quantification of ADRβ2, IL10, NR3C1, TNFR1, TNF⍺, with RPP30 appearing to
be the most suitable normalizer (CV = 10%). The mRNA expression patterns appeared to
parallel behavioral reports of one elephant displaying consistent high-anxiety. Together,
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these findings indicate that differential expression of stress-responsive genes in blood is a
promising avenue for better biomarkers capable of tracking stress and assessing
wellbeing in zoo animals, which will be important in optimizing health status &
reproductive capacity in these animals. This study also demonstrates that it is possible to
design on-target primers for specific transcripts in unassembled species, such as giraffes,
with whole genome sequences of related species.
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Introduction
Multiple models of maternofetal stress including inflammation have been shown
to induce intrauterine growth restriction (IUGR), which is linked to lifelong dysfunction
in humans and animals (Cadaret et al., 2018; Yates et al., 2018). Inflammation induced
by bacterial lipopolysaccharide (LPS) endotoxin have previously been linked to changes
in immune cells and specifically with a shift toward a pro-inflammatory phenotype in
circulating white blood cells (WBC) (Medzhitov, 2008; Martinez et al., 2014; Yuan et al.,
2016). This pro-inflammatory phenotype favors increases in TNF⍺ and IL-6, as well as
their respective receptors TNFR1 and IL6R (Duque and Descoteaux, 2014; Martinez et
al., 2014) in concert with a marked decrease in the expression of anti-inflammatory
cytokines such as IL-10 (Opal and DePalo, 2000; Duque and Descoteaux, 2014). Stressresponsive signaling pathways activated by glucocorticoids and catecholamines have
been implicated in exacerbating this pro-inflammatory phenotype under chronic
conditions, which further increases inflammation and contributes to the development of
chronic diseases (Medzhitov, 2008; Liu et al., 2017). Therefore, the objective of Exp. 1
was to determine the effects of sustained maternofetal inflammation at mid-gestation on
maternal and fetal mRNA profiles in whole blood pellets
Modern zoos are expected to maintain high standards for animal wellbeing in a
diverse population of wildlife. Zoo animals experiencing novel stressors may be at
greater risk for inflammatory diseases, and opportunistic infections in environments that
differ from their natural habitat. The most common indicators used to measure the
physiological stress of zoo animals is glucocorticoid concentrations in feces, and to lesser
extent blood, urine, or saliva. However, this assay is limited by the individual variation
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between group-housed animals (Cockram, 2002; Wolfensohn et al., 2018), the natural
circadian variations in glucocorticoids, that glucocorticoid release is also associated with
non-stress stimuli, and that glucocorticoids are not always elevated by stress (Cockram,
2002). Other measurements, such as the leukocyte or neutrophil activation test have been
previously shown to be possible markers of stress levels (Honess et al., 2005). However,
these tests only loosely estimate overall stress through leukocyte responsivity. Finally,
the majority of published studies on animal wellbeing focus on markers that only apply to
mammalian species, which represent one part most zoos taxonomic population
(Wolfensohn et al., 2018). The objective of Exp. 2 was to determine if we could measure
stress-responsive gene transcripts as potential biomarkers in whole blood from elephants,
giraffes, and cheetahs using ddPCR. We further sought to design cross-species primers
for a species with only a whole genome sequence available (giraffes), which would allow
for the possibility of future research to be applied to a broader range of species.
Materials and Methods
Exp. 1
Animals and experimental design.
All procedures were approved by the Institutional Animal Care and Use
Committee at the University of Nebraska-Lincoln. Studies were performed at the
University of Nebraska-Lincoln Animal Science Complex, which is an AAALAC
International accredited institution. Timed-pregnant Sprague-Dawley rats (Envigo,
Indianapolis, IN) were purchased and delivered on day 6 of gestational age (dGA). On
dGA 8, rats were moved to individual housing, fed ad libitum commercial rat chow, and
weighed daily. From dGA 9 to 11, rats were injected (IP) daily with 250µl saline
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(control, n=7), 100µg/kg BW of lipopolysaccharide (LPS) from E. coli O55:B5 (SigmaAldrich, ST. Louis, MO, USA) in 250µl saline to create maternofetal inflammationinduced IUGR (MI-IUGR, n=8), or LPS concurrent with 7.5mg/kg BW of meloxicam
(LMX, n=10). Blood samples were collected from dams via saphenous vein puncture at
0, 6, and 54hr after initial injection. On dGA 20, rats were euthanized by decapitation
under heavy isoflurane anesthesia after maternal blood samples were collected via heart
puncture. Pooled fetal blood samples were collected for each litter via exsanguination.
All blood samples were centrifuged (14,000 x g, 2 minutes, 4ºC) and blood pellets were
re-suspended in TRI Reagent® (Sigma-Aldrich) at a 3:1 ratio to original blood volume,
vortexed, and stored at -80ºC.
RNA extraction and preparation.
Gene transcripts were measured in maternal blood samples taken at 0, 6, and 54hr
after the first injection. Fetal blood gene transcript expression was measured from
samples taken at dGA 20 as described above. To extract RNA, samples suspended in TRI
Reagent® were thawed to room temperature and homogenized. Chloroform (160µl) was
added to each sample and vortexed for 10-15 seconds before incubating at room
temperature for 5 minutes. All samples were then centrifuged (12,000 x g, 15 minutes,
4ºC), and the aqueous layer transferred to a QiAmp® shredder column (Qiagen,
Germantown, MD, USA). Extraction was then performed using the QiAmp® RNA Blood
Mini Kit (Qiagen), including on-column DNase digestion with the RNase-Free DNase set
(Qiagen) according to manufacturer recommendations. Isolated RNA concentration and
quality was analyzed on a Take3 plate with an Epoch Spectrophotometer System
(BioTek, Winooski, VT, USA) to ensure that all samples produced a 260/280 ratio ≥ 2.0.
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RNA isolates were reverse transcribed into cDNA using the QuantiTect reverse
transcription kit (Qiagen). Samples were diluted at 1:10 in RNase-free water (Qiagen)
and stored at -20ºC.
Primer design.
Primers for the analysis of IL6R, TNFR1, and FN14 expression were purchased as
PrimePCR ddPCR primers (Bio-Rad, Hercules, CA, USA) specific to the EvaGreen
supermix based assay. Primers for the analysis of TNFA, YWHAZ, and INFGR1 were
designed using the Primer3 system (Untergasser et al., 2012), according to the
recommended criteria for use with ddPCR Evagreen supermix based assays (Bio-Rad,
Hercules CA, USA). These were validated for target specificity using both National
Center for Biotechnology and Information primer design tools and the BLAT function of
the UCSC genome browser (University of California, Santa Cruz, CA, USA). Optimized
sequences were purchased from Integrated DNA Technologies (IDT; Coralville, IA,
USA), re-suspended in RNase free water to a concentration of 100µm. Forward and
reverse primer solutions were mixed to create a 10µM working solution, which was
stored at 20ºC. gBlocks® Gene Fragments were also purchased from IDT for YWHAZ,
TNFR1, FN14, and IL6R.
mRNA quantification.
Droplet digital PCR (ddPCR) analysis was performed in duplicate using the
QX200 system (BioRad). EvaGreen Supermix (11µl) at a 2X concentration was added to
individual wells of a colorless 96-well PCR plate (Sigma). A 10µM working solution of
IDT designed primers (0.22µl), or PrimePCR primers (1µl) for transcripts of interest was
added to individual wells before 2µl of 1:10 cDNA sample was added. RNase free water
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was then added to the master mix for a total volume of 22µl per well. RNase-free water
was used as the negative template control, and gBlocks® Gene Fragments (IDT) for
YWHAZ, TNFR1, Fn14, and IL6R were used as positive controls to determine the
expression levels of those target genes. Each gene was analyzed on an individual 96-well
plate containing all fetal and maternal samples, with a negative and positive control.
Mixtures were vortexed and centrifuged (3,000 x g, 3 minutes, 20ºC) before
approximately 20,000 droplets were generated using a QX200 Droplet Digital Generator
(Bio-Rad). Droplets were transferred to a QX200 compatible ddPCR 96-well plate (BioRad) and thermal cycled on a C1000 Touch Thermo Cycler (Bio-Rad). Conditions were
set according to pre-determined annealing temperatures of designed and PrimePCR
primers. Expression was quantified using a QX200 Droplet Reader (Bio-Rad), and results
analyzed using QuantaSoft Analysis Pro Software (Bio-Rad). The complete list of
optimized primers for each target gene is summarized in Table 4-1.
Statistical Analysis.
All data were analyzed by ANOVA using the mixed procedure of SAS (SAS
Institute, Cary, NC, USA) to determine experimental group effects. Repeated measures
were used for serial maternal samples. Gene transcript data are expressed as transcript
copies per µl, normalized to copies per µl of YWHAZ. Rat (dam) was considered the
experimental unit and experimental group was the group for all variables. Fetal values
reflect the pooled fetal samples analyzed in each dam’s litter. All data are expressed as
mean ± standard error.
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Exp. 2
Animals and experimental design.
All sample collections were approved by the Institutional Animal Care and Use
Committees at the University of Nebraska-Lincoln and Omaha’s Henry Doorly Zoo and
Aquarium. Giraffe (n=1) and elephant (n=3) samples were collected into TempusTM
blood RNA tubes (Applied Biosystems, Foster City, CA, USA), and stored at 4ºC for a
max of 72hr. Cheetah samples (n=2) were collected using the TRI Reagent (SigmaAldrich) protocol described in Exp. 1.
RNA extraction and preparation.
Elephant and giraffe samples collected into Tempus™ blood RNA tubes were
extracted using manufacturer recommendations. Cheetah samples collected in TRI
Reagent® were extracted using the protocol described for Exp. 1. Quality of RNA was
determined and extracts were reverse transcribed as in Exp. 1. cDNA was stored at -20ºC
as a 1:10 dilution for elephant and cheetah samples, and undiluted for giraffe samples.
Probe design.
Probes for analysis of cheetah and elephant mRNA expression were designed
using the Primer3 system (Untergasser et al., 2012), according to the recommended
parameters for use with ddPCR supermix for probe (No dUTP) based assays (Bio-Rad).
Sequences were validated using the protocol in Exp. 1 are summarized in Tables 4-2 and
4-3. Optimized sequences were purchased as PrimeTime® probe assays (IDT), resuspended in IDTE buffer to a stock concentration of 10X, and stored at -20ºC. Before
use, probe assays were prepared using the recommended 10X stock concentration
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protocol to yield a final 1X concentration of 500nM for primers and 250nM for probes
per reaction.
Cross-species primer design.
Primers for the analysis of giraffe mRNA expression were designed using a crossspecies protocol and are summarized Table 4-4. Sheep (Ovis ares) and cow (Bos taurus)
assemblies were obtained from the Ensembl database for each target transcript. The
coding regions were then paired against the whole genome sequence (NCBI database) for
the giraffe (Giraffa camelopardalis tippelskirchi) using the BLAST function (NCBI) to
determine identity percentage. Sequence segments with at least 99% identity for target
coding regions of both sheep and cow were then aligned using MultAlin. Primers were
designed using Primer3 (Untergasser et al., 2012) including only sequence segments that
had 99% identity across all three species. Primers also included at least one identified
exon that was conserved between cow and sheep sequences. Identified sequences for IL6,
ADRB2, TNFA, and RPL19 were obtained and validated using the same protocol as
described in Exp. 1. Optimized sequences were purchased (IDT) and working solutions
were stored at -20ºC.
ddPCR Analysis.
The giraffe sample, was analyzed with the EvaGreen supermix for ddPCR
protocol as described in Exp. 1. Cheetah and elephant ddPCR analysis was also
performed as described in Exp. 1, with some modifications for probes. Quantification
was performed in duplex format by co-amplifying the target transcript of interest labelled
with FAM and the normalizer genes (RPP30, RPL19, and YWHAZ) labelled with HEX.
Each target transcript was quantified in duplex with each normalizer gene to accurately
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determine fold change and overall expression during analysis. A 2X concentration of
QX200 ddPCR supermix (No dUTP) for probe-based assays (Bio-Rad) at a final
concentration of 1X in each 22µl was used in place of the EvaGreen supermix.
Conditions for thermal cycling were also modified to fit the pre-determined annealing
temperatures of designed PrimeTime® assays. Data are analyzed using QuantaSoft
Analysis Pro Software (Bio-Rad) with expression determined for each target
gene/normalizer gene combination.
Statistical analysis.
Expression for all three species from ddPCR analysis was calculated as the
number of transcript copies of target transcript per µl normalized to the number of
transcript copies of each available reference transcript per µl. The coefficient of variation
(CV) was determined for all references available in each group to determine their
suitability as normalizers. The reference used was RPL19 for cheetahs, RPP30 for
elephants, and RPL19 was targeted in giraffes.
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Results
Exp. 1
Fetal TNFR1 tended to be increased (P < 0.10) but not when meloxicam was
concurrently administered (Figure 4-1A). Fetal IL6R was reduced (P < 0.05) by MI and
was not improved by concurrent meloxicam (Figure 4-1B). Maternal TNFR1 was
increased (P < 0.05) by LPS at 6hr after initial injection and was not affected by
meloxicam administration (Figure 4-2). No other genes differed among groups.
Exp. 2
In cheetah samples, the expression of ADRβ2 (β2 Adrenoceptor), IL10
(Interleukin 10), IL6R (Interleukin 6 Receptor), NR3C1 (Glucocorticoid Receptor),
TNFR1 (TNF⍺ Receptor 1), and TNF⍺ (Tumor Necrosis Factor Alpha) was successfully
quantified (Figure 4-3). Among the three normalizers, RPL19 (Ribosomal Protein L19)
was found to have the lowest CV (7%) among the samples. In elephant samples, the
expression of ADRB2, IL10, NR3C1, TNFR1, and TNFA were successfully quantified
(Figure 4-4). RPP30 (Ribonuclease P/MRP Subunit P30) was the reference transcript
with the lowest CV (10%). Cross-species primers were able to quantify ADRB2 and
TNFA in our giraffe sample, but no other transcript was successfully quantified by our
primers.
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Discussion
In Exp. 1, we found that injection of LPS endotoxin caused temporal increases in
the expression of TNFA and its receptor TNFR1 in circulating leukocytes of pregnant rats.
We also demonstrated that MI at mid-gestation leads to lasting inflammatory adaptations
in the transcript expression of the cytokine receptors IL6R and TNFR1, which were
observed at term in fetal blood. These results indicate that inflammation and stress lead to
changes in the transcriptome of circulating leukocytes, which can be used as biomarkers
for stress assessment. They further demonstrate that activation of these pathways during
mid-gestation can have lasting effects on the expression patterns of fetal leukocytes.
In Exp. 2 we determined if these biomarkers could be quantified in zoo species as
well. We were able to successfully design and implement ddPCR probes for a number of
immunological and stress-responsive genes in cheetahs and elephants, which
demonstrates the applicability of assays targeting these biomarkers to a broad range of
mammals. We were also able to successfully utilize a cross-species primer design
approach to target and analyze some but not all transcripts in giraffes. This represents, to
our knowledge, the first successful attempt at designing cross-species primers for these
targets in this unassembled species.
We chose the biomarkers in this study based off of our previous experiences, and
on the complex interactions between the stress, reproductive, and immune systems. We
chose to target the receptors for glucocorticoids (NR3C1) and catecholamines (ADRβ2),
as these pathways play a role in immunomodulation, the stress response, and even
reproductive success in mammals (Padgett and Glaser, 2003; Slavich and Irwin, 2014;
Liu et al., 2017; Levine and Muneyyirci-Delale, 2018). The results of Exp. 1 demonstrate
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that the blood expression patterns of the cytokines TNF⍺ and IL6, as well as their
receptors, are modulated in response to inflammation. Previous studies in mammals also
demonstrate these cytokines pleiotropic effects on everything from mental health (Slavich
and Irwin, 2014; Vogelzangs et al., 2016) to complex interactions with the reproductive
and stress response systems (Morey et al., 2015; Costanza and Pedotti, 2016; Liu et al.,
2017). Finally, IL-10 was chosen because it is a major immunoregulatory and antiinflammatory cytokine (Opal and DePalo, 2000; Couper et al., 2008). Analysis of IL-10
expression would allow future assays to increase the window for detection of infection
and inflammation, as its rise would be concurrent with decreasing levels of proinflammatory cytokines. It is worth noting that all of these pathways and biomarkers have
also been identified in invertebrates and non-mammals, allowing them to be applicable to
a more diverse range of species (Janeway et al., 2001; Müller et al., 2008; Adamo, 2012).
Together, the results of both experiments represent a promising avenue for future
research into monitoring animal wellbeing, reproductive programs, and disease detection
in zoos with diverse taxonomic populations. The biomarkers and associated pathways we
chose to pursue in these experiments are evolutionarily conserved across most vertebrates
and invertebrates (Müller et al., 2008; Flajnik and Kasahara, 2010; Adamo, 2012). As
demonstrated in experiment 1, some of these stress biomarkers are differentially
expressed in whole blood after inflammation which makes them viable targets for
assessing disease states in animals. Other studies in mammals and invertebrates have
demonstrated these markers are affected by stress, disease, reproductive status, and many
other components of overall animal wellbeing (Adamo, 2012; Costanza and Pedotti,
2016; Vogelzangs et al., 2016; Liu et al., 2017). Thus, the ability to analyze these
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expression patterns in while blood represents a new opportunity to improve our
understanding of wellbeing in a broad range of exotic species.
A high standard of wellbeing in diverse range exotic species is a goal for zoos
(Wolfensohn et al., 2018). Proper care requires accurate and reliable assessment of
physiological stress and health, which is difficult to tailor to the specific needs of species
who may be at greater risk of mortality in these novel environments with current
techniques that include the measurement of cortisol from the feces, urine, or saliva of
animals and behavioral assessments (Wolfensohn et al., 2018). Both of these measures
are limited due to individual variability, circadian variation, complex collection of
samples of group housed populations, and their association with other non-stress stimuli
(Cockram, 2002; Wolfensohn et al., 2018).
We conclude that whole blood expression of stress-responsive mRNA biomarkers
is altered due to inflammation. These and other evolutionarily-conserved biomarkers can
be quantified in elephant, cheetah, and giraffe blood samples using species specific
ddPCR probes and primers. We were able to design probes specific to most of our
intended targets and were also successful in designing cross-species primers capable of
quantifying targets in the giraffe, which is currently unassembled. It is of note that we
were able to corroborate our findings in elephants with behavioral observations from
keepers that indicated a high anxiety female within this family group. The results of our
studies represent a promising future for the development of a comprehensive assay that
can be used to identify and assess stress in diverse populations of animals housed in zoos.
Further research is of course needed to determine the applicability of such assays to other
non-mammalian species, and which additional biomarkers might be included.
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Table 4-1. Rat primer sequences for ddPCR
Gene
TNFA
INFGR1

Protein

Primer Sequence

Tumor necrosis
factor alpha
Interferon Gamma
Receptor 1

AACTCCCAGAAAAGCAGCA
AGAAGAGGCTGAGGCACAGA
TGAAACATTACAGGAGTGGG
GGACGCTATGTTCTGTATGT
CACTGATCCAGTGAGGAGCA
GGCAATTAGACACCCTGGAA
CACGAGCCATCATGAAGAGA
GCCAAGGTGCTTGGATTTTA
TTGTAGGATTCAGCTCCTGTC
CTCTTACAGGTGGCACGAAGTT
CCGAGCTGTCTAACGAGGAG
GAGACGACCCTCCAAGATGA

FN14

TWEAK Receptor

IL6R

IL-6 Receptor

TNFR1

TNFα Receptor 1

YWHAZ

14-3-3 protein ζ

Product
Size

Accession
Number

200

NM_012675.3

48

NM_053783.1

88

NM_181086

96

NM_017020

109

NM_013091

88

NM_013011
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Table 4-2. Cheetah primer and oligo sequences for ddPCR.
Cheetah Sequences
Gene

Protein

Primer Sequence

Product
Accession Number
Size

ddPCR Primers
CGGGAATGGACAGTCACAGG
60S Ribosomal
CGTCAGCAGATCCGGAAACT
RPL19
Protein L19
HEX-ATGGGCTGATCATCCGGAAA-ZEN/IB FQ
TGGTCTGGTAGGAAACGGCA
Tumor necrosis factor
TCTTCAGGGGCCAAGGATGT
TNF⍺
alpha
6-FAM-TTCCACACATGTGCTCCTCA-ZEN/IB FQ
GTCCCGGTACACTGTGCAAG
AGCTGCTCCAAATGCCGAAA
TNFR1
TNFα Receptor 1
6-FAM-ATGTACCAGGTGGAGATATCTC-ZEN/IB
FQ
CTCCGCAGCCAGTGAATTGT
GCTGAGTGATGTGGTGACCG
IL6R
IL-6 Receptor
6-FAM-CCAACGTGACCCTGACCTG-ZEN/IB FQ
GTGCTGTTTGATGTCCGGGT
GACTTTAAGGTGAGGGCCCG
IL-10
Interleukin 10
6-FAM-TACTTGGAGGAGGTGATGCC-ZEN/IB FQ
GTCTGGGAAAGGAACCGTGC
Nuclear receptor
CGAACGGGACAGAAAGGTGG
NR3C1 subfamily 3 group C
6-FAM-TCCGAGCACCACGTGATC-ZEN/IB FQ
member 1
GCTGAGATTTTGGGCGTGGA
GGTCTTTCAGGTGGCCCAAA

ADRβ2

Adrenoceptor beta 2

100

XM_015078591

100

XM_015082146

100

XM_027074099

100

XM_027048711

100

XM_027074588

100

XM_027042531

100

XM_015079810

6-FAM-GATCGACAAATCTGAGGGCC-ZEN/IB FQ

Ribonuclease P/MRP
subunit p30

CTCTCAGACAGCCCGAACAG
TGTCTAGTGCTGCGGAAAGG
HEX-AAGAGGCCCATACGATGTGG-ZEN/IB FQ

100

XM_015061888

Tyrosine 3monooxygenase/trypt
ophan 5YWHAZ
monooxygenase
activation protein zeta

AAGGGGCCGGCTAACATTTG
AGGGGAATTAGTGGTGGGCA
HEX-AGTGTCTACCCCAATTCTGGT-ZEN/IB FQ

100

XM_027064119

RPP30
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Table 4-3. Elephant primer and oligo sequences for ddPCR.
Elephant Sequences
Gene

Protein

Primer Sequence

Product
Accession Number
Size

ddPCR Primers
GAGCACTGACAGAGACCGAC
Ribonuclease P/MRP
CTTCCAGCGTGCAAGAAAGC
RPP30
subunit p30
HEX-AAGTGTGAGGGCTGAGCAG-ZEN/IB FQ
CTCAACGTCCCGGATCATGC
Tumor necrosis factor
GCTCCACCATCTCCCAGCTA
TNF⍺
alpha
6-FAM-CCAAAGGACACCATGAGCAC-ZEN/IB FQ
GGGAGGGGAAGAGACTGCAT
GTAGGGCCAAGAAAGGGTGC
TNFR1
TNFα Receptor 1
6-FAM-AGGGAAAGGACAAGTGGAGT-ZEN/IB FQ
CCAGGCTTCCATCCCACCTA
GTCTCTCTCCTCTGCACCGT
IL6R
IL-6 Receptor
6-FAM-GCTCTCTTTTCCCACAGTGC-ZEN/IB FQ
CTCTGGGGCCTACTGTTCCA
CGGCGCTGTGTGAGTAGAAG
IL-10
Interleukin 10
6-FAM-TTTTTCCCCTGGAGGCTGTC-ZEN/IB FQ
AGACTGACCTGGTATGGGGC
Nuclear receptor
AAGCCAACACCTCTCCCAGA
NR3C1 subfamily 3 group C
6-FAM-ACCTTAGTACAGCAAGGGTTGT-ZEN/IB
member 1
FQ
GCAGGTCTCTTCGGCATAGC
ACCTCCTTCTTGCCCATCCA

ADRβ2

100

XM_003409241

100

XM_023541361

100

XM_023549042

100

XM_023554017

100

XM_023548359

100

XM_003404576

100

XM_003404840

AGGCTGTGATACATGTGGCG
AGGATGAGAATTCTGCGCCG
HEX-CTGCTCAGGAGATACCGTGA-ZEN/IB FQ

100

XM_010594387

TCAACCGCTAGTGGGAGGAC
CAGCATGCTCGAGTCCCATC
HEX-TGTCATTCCACCTCACCTGA-ZEN/IB FQ

100

XM_010588433

Adrenoceptor beta 2

6-FAM-AATGCACTGGTACCGGGC-ZEN/IB FQ

RPL19

60S Ribosomal
Protein L19

Tyrosine 3monooxygenase/trypt
YWHAZ
ophan 5monooxygenase
activation protein zeta
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Table 4-4. Giraffe primer sequences for ddPCR.
Giraffe Sequences (Assembly #: GCA_001651235.1)
Gene

Protein

Primer Sequence

Product
Accession Number
Size

ddPCR Primers
126

Cow: XM_587778
Sheep:
XM_012186026

TCTACTTTGGGATCATCGCC
CAGGCCTCACTTCCCTACAT

201

Cow:
XM_005223596
Sheep:
XM_012100437

Interleukin-6

TCAGCCCTCTAGTGGTGTGA
GCATCCATCTTTTTCCTCCA

156

Cow:
NM_174674
Sheep:
NM_001166185

Adrenoceptor beta 2

GGGGCAGCTTTGGTTGTTTT
AAGCACACTCCAGTCAAGGG

113

Cow:
NM_174231
Sheep:
NM_001130154

RPL19

60S Ribosomal
Protein L19

GGGCCTTGTGTAGAAGAGCA
ACACGTTACCCTTCACCTTCA

TNF⍺

Tumor necrosis factor
alpha

IL-6

ADRβ2
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Fetal Gene Expression

TNFR1
mRNA copies/Ywhaz
copies

7
6

P = 0.06

a

8
a

5
4

b

3
2
1
0

Control

TNFR1
Matern. Inflam.

Matern. Inflam. + Melox.

B

IL6R
mRNA copies/Ywhaz
copies

9

A

4.0

P = 0.05

a

3.5
3.0
2.5
2.0

b

b

1.5
1.0
0.5
0.0
IL6R

Figure 1

Figure 4-1. Gene expression (ddPCR) for (A) TNFR1 and (B) IL6R in control (n=7),
MI-IUGR (n=8), and MI-IUGR + Meloxicam (n=10) rat fetuses at term. a,b means
with different superscripts differ.
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Maternal TNFR1 Expression
TNFR1 mRNAcopies/YWhaz
copies

45%

b

40%

b

35%
30%
a

25%
a

20%
15%
10%

a

a

a

a

a

5%
0%
Time 0

Time 6
Maternal TNFR1

Time 54

Figure 2

Figure 4-2. Gene expression (ddPCR) for TNFR1 in maternal whole blood samples
collected at 0, 6, and 54hr after treatment onset of LPS injection. a,b means with
different superscripts differ (P < 0.05). Control (n=7), MI-IUGR (n=8), MI-IUGR +
Meloxicam (n=10).
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Cheetah Gene Expression
Percent mRNA Expression/RPL19
Expression

0.15%
0.11%

0.10%
0.07%

0.06%
0.01%

0.05%
0.02%

0.01%

0.00%

5%
4%
2.77%

3%
1.63%
1.10%

0.94%

2%
0.95%

0.78%

1%
0%

Sukari
ADRB2

23964
IL10

TNFa

IL6R

NR3C1

TNFR1

Figure 3

Figure 4-3. Gene expression (ddPCR) for ADRB2, IL10, TNFA, IL6R, NR3C1, and
TNFR1 in whole blood samples collected from cheetahs (n=2).
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Elephant Gene Expression
Percent mRNA Expression/RPP30
Expression

5.50%
4.50%

4.22%

3.50%
2.16%

2.50%

1.33%

1.50%

1.18%

0.60%

0.51%

0.50%
80%
57.95%

60%

49.39%
35.83%

28.53%

33.92%
16.47%

8.93%

13.04%

6.75%

17414

22661

40%
20%
0%

1019
IL10

NR3C1

ADRB2

TNFa

TNFR1

Figure 4

Figure 4-4. Gene expression (ddPCR) for ADRB2, IL10, TNFA, NR3C1, and TNFR1
in whole blood samples collected from elephants (n=3).
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